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Abstract 
 
Pradimicin is a novel antibiotic consisting of a benzo[a]naphthacenequinone aglycon, an 
amino acid and a disaccharide fragment. In this study, the α-analogue of the disaccharide 
derivative of pradimicin A was synthesized in its protected form. 
The disaccharide moiety of pradimicin A was built up from a suitably protected, 
commercially available D-xylose derivative and the amino sugar part, synthesized from L-
threonine. The synthesis of the target amino sugar started with the conversion of the L-
threonine derived aldehyde to the desired E-enoate via a modified Horner-Wadsworth-
Emmons olefination. Ruthenium-catalyzed cis-dihydroxylation of the double bond 
produced a mixture of anti- and syn-aminodiols, of which the former was lactonized under 
acidic conditions. Platinum-catalyzed reduction of the lactone produced a mixture of 
lactols, which upon treatment with DAST provided a mixture of α- and β-fluorinated 
amino sugar derivatives. Both the α- and β-fluorides were transformed to suitable glycosyl 
fluorides of pradimicin A via successive N-methylation by MeI/Ag2O, deacetylation and 
regioselective benzoyl protection at the C2-position. Final coupling of the α-glycosyl 
fluoride with the D-xylose derived thioglycoside donor by NBS furnished the protected α-
analogue of the disaccharide fragment of pradimicin A. 
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 Symbols and abbreviations 
 
Ac   acetyl 
Bn   benzyl 
BOC   t-butoxycarbonyl 
BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium 
hexafluorophosphate 
Bz   benzoyl 
Cbz   benzyloxycarbonyl 
CSA   camphorsulfonic acid 
DAST   diethylaminosulfur trifluoride 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC   dicyclohexylcarbodiimide 
DEAD   diethyl azodicarboxylate 
DIBAL-H  diisobutylaluminium hydride 
DMAP   4-dimethylaminopyridine 
DME   1,2-dimethoxyethane 
DMF   N,N-dimethylformamide 
DMP   2,2-dimethoxypropane 
DMSO   dimethyl sulfoxide 
dppf   1,1'-bis(diphenylphosphanyl)ferrocene 
EDCI   1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
Fmoc   fluorenylmethyloxycarbonyl 
fod   6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionate 
HWE   Horner-Wadsworth-Emmons 
IBAL   isobutyraldehyde 
 IPA   isopropyl alcohol 
KHMDS  potassium hexamethyldisilazane 
mCPBA  m-chloroperbenzoic acid 
MOM   methoxymethyl 
Ms   methanesulfonyl 
NBS   N-bromosuccinimide 
NIS   N-iodosuccinimide 
NMO   N-methylmorpholine N-oxide 
PCC   pyridinium chlorochromate 
PDC   pyridinium dichromate 
PMP   p-methoxyphenyl 
PPTS, PTSA  pyridinium p-toluenesulfonate 
pyr   pyridine 
salen   N,N-bis(salicylidene)ethylenediamino 
TBAF   tetra-n-butylammonium fluoride 
TBDPS  t-butyldiphenylsilyl 
TBS   t-butyldimethylsilyl 
TBSOTf  t-butyldimethylsilyl trifluoromethanesulfonate 
Tf   trifluoromethanesulfonyl 
TFA   trifluoroacetic acid 
TFAA   trifluoroacetic anhydride 
THF   tetrahydrofuran 
TMS   trimethylsilyl 
TPAP   tetra-n-propylammonium perruthenate 
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 Preface 
 
Pradimicin is a novel antifungal antibiotic first isolated from a soil sample collected in Fiji 
Island in the late 80’s. Thus far, several pradimicin analogues have been isolated, but the 
entire molecule has not been totally synthesized. Because of its pharmaceutical potential, 
there has been strong interest towards the total synthesis of pradimicin. 
In Chapter 1, the structure and biological activity of pradimicin is introduced. Chapter 2 
reviews the amino acid based synthetic methods for the preparation of amino sugars and 
Chapter 3 presents the published synthetic approaches to pradimicin. Chapters 4 and 5 
describe my own experimental work concerning the synthesis of the disaccharide fragment 
of pradimicin A, starting from the amino acid L-threonine. 
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1. Introduction to pradimicins 
 
1.1. Structure of pradimicins 
 
Pradimicin A is a novel antifungal antibiotic first isolated from a soil sample collected in 
Fiji Island in the late 80’s.1 Several pradimicin analogues, designated as pradimicin B, C, 
D, E etc. have been later isolated or produced biosynthetically.2-9 The pradimicin 
antibiotics consist of a benzo[a]naphthacenequinone core, an amino acid and a 
disaccharide (Fig. 1) In order to explore the antifungal activity of different pradimicin 
analogues, modifications of the original structure have been performed, including 
replacement of the D-alanine moiety by another amino acid10 or modification of the 
aglycon11 or the sugar part.12 The water-solubility of pradimicin A has been improved by 
modification of the amino group of the disaccharide13 and replacing the D-alanine moiety 
by D-serine.14 Some structures of the pradimicin analogues are presented in Figure 1. 
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Figure 1. Structures of some pradimicin analogues. 
 
1.2. Biological activity 
 
Pradimicin A has shown moderate in vitro activity against a wide variety of fungi and 
yeasts and in vivo therapeutic activity against systemic fungal infections caused by 
Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans.1,15 Pradimicins 
have also shown inhibitory effect on human immunodefiency virus (HIV) in vitro16 and 
antiviral activity against influenza virus.1a,15 The biological activities of pradimicins are 
attributed to the potentially specific binding to cell wall oligosaccharides of fungi or viral 
surfaces. At this time, the proposed mechanisms of action of pradimicins are still 
speculative, but it has been suggested that the pradimicins form a ternary complex with D-
mannoside and calcium on the Candida cell wall, and this ternary complex formation 
results in membrane disruption and fungal cell death.17 In detail, pradimicin first 
19 
recognizes and binds to D-mannoside to produce the mannan-pradimicin conjugate, which 
is subsequently complexed with calcium to form a ternary complex on the cell wall. It is 
believed that only the free C-18 carboxyl group of pradimicin binds to calcium whereas 
the C-5 disaccharide moiety is essential for the stereospecific recognition of and binding to 
D-mannopyranoside by constructing a specific mannose-binding pocket with the 
pradimicin aglycon.18 The stereochemistry of the amino acid moiety in the pradimicin 
skeleton plays also an important role in the binding process: when the D-alanine moiety of 
pradimicin A was replaced by L-alanine to form 17-epipradimicin, virtually no binding to 
the mannose unit nor antifungal activity was observed.19 It was reasoned that the inability 
of L-alanine to bind to the cell surface was due to the steric factors, caused by the change 
in the stereochemistry. 
BMS-181184 (Fig. 1), a water-soluble D-serine analogue of pradimicin A having its 
amino functionality of the disaccharide unit replaced by a hydroxy group20 is currently 
targeted for clinical drug development. 
20 
2. Synthesis of amino sugars from amino acids 
 
Amino sugars are commonly synthesized from readily available and relatively inexpensive 
carbohydrates as principal intermediates, usually requiring multistep synthetic 
transformations, but also non-carbohydrate precursors have gained interest as useful 
starting materials for the synthesis of deoxyaminohexoses.21 Some examples of the non-
carbohydrate based approaches include direct amination of carbocycles,22 transformation 
of isoxazolines,23 the use of hetero Diels-Alder cycloaddition,24 [3+2] cycloaddition of 
nitrones with vinylene carbonate25 and the exploitation of naturally occurring substrates 
such as amino acids26 and lactic acid.27 In this chapter, the amino acid based syntheses of 
amino sugars are reviewed. 
 
2.1. Monoamino dideoxyhexoses 
 
2.1.1. Mycaminose 
 
In 1974, Yamada and Koga employed L-alanine as the chiral starting material in the 
synthesis of α-L-mycaminoside 9 (Scheme 1).28 In the transformation of L-alanine to α-L-
mycaminoside, the chirality of the product is inherited from the starting amino acid as 
shown in Figure 2. 
 
O OMe
OHHO
NMe2
Me
*
Me CO2H
NH2
*
 
   L-Alanine         α-L-Mycaminoside 
Figure 2. 
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The first step of the synthesis was nitrous acid deamination in acetic acid, producing 2-
acetoxypropionic acid 1 with 96 % retention of configuration. Formation of acid chloride 
with thionyl chloride, followed by treatment with Grignard reagent provided alkyne 3. 
Hydrogenation of the triple bond and subsequent deacetylation afforded cis-alkene 4, 
which was cyclized in refluxing carbon tetrachloride in the presence of phosphoric acid to 
form an anomeric mixture of L-hex-2-enopyranosid-4-uloses 5 and 6 (ratio ca. 1:2). After 
purification by column chromatography and recrystallization, the optically pure α-anomer 
6 was reduced by lithium aluminum hydride to give the unsaturated anti-alcohol 7. 
Epoxidation with m-chloroperbenzoic acid, followed by treatment with saturated aqueous 
dimethylamine produced α-L-mycaminoside 9. 
 
OMe
O
OMe
O
1 3
56
O OMeMe
7
O
OMe
OHHO
Me2N
Me
i
iv, v
vi
vii
viii ix
ii
2
iii
OMeOMe
HO
O OMeMe
8
HO
O
L-Ala
Me CO2H
NH2
Me CO2H
OAc
Me COCl
OAc
Me
OAc
O
CH(OMe)2
4
Me
OH
O
CH(OMe)2
9
47% 84% 67%
  60% 
overall
77% 67%
74%
 
 
Scheme 1. i) HNO2, AcOH; ii) SOCl2; iii) BrMgC≡CCH(OMe)2; iv) H2, Pd/BaSO4, 
EtOAc, quinoline; v) NaOH, dioxane; vi) CCl4, H3PO4, heat; vii) LiAlH4, Et2O; viii) 
mCPBA, benzene; ix) aq. Me2NH, 80 °C. 
 
 
 
22 
2.1.2. Fucosamine 
 
Polt and Sames have employed L-serine derived Schiff base 10 in the enantioselective 
synthesis of N-methyl-D-fucosamine 17 (Scheme 2)29 which is the amino sugar component 
of the enediyne anticancer antibiotic neocarzinostatin.30 
 
Me
MeO OH
O O O
O
O O
O
HO
OMe
HO
MeHN
N-Methylfucosamine
 
 
Figure 3. Neocarzinostatin chromopore. 
 
In the beginning of the synthetic sequence, the protected L-serine derived methyl ester 
10 was reduced to the corresponding aldehyde, followed by addition of alkenyllithium to 
form the syn-amino alcohol 11 with high diastereoselectivity (> 20:1). Osmium-catalyzed 
dihydroxylation of the double bond afforded a 6:1 mixture of syn-anti-syn and all-syn-
aminotriols which were separated by chromatography after in situ acetylation, providing 
the desired triacetate 12. Reduction of 12 to secondary amine, followed by N-methylation 
and cleavage of the silyl protection produced the primary alcohol 14, which was converted 
to the α-amino aldehyde 15 by Swern oxidation. Deacetylation of 15 by weak Brønsted 
base potassium cyanide in anhydrous methanol gave the N-protected N-methyl-D-
fucosamine intermediate 16 as a mixture of pyranose and furanose anomers. The Brønsted 
base was used due to the lability of aldehyde 15 towards basic reaction conditions. Finally, 
hydrogenolysis of the benzhydryl group of compound 16 generated N-methyl-D-
fucosamine 17 in 13 % overall yield. 
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Scheme 2. i) DIBAL-H, TRIBAL, CH2Cl2, -78 °C; ii) LiCH=CHCH3, toluene, -78 °C → 
rt; iii) K2OsO2(OH)4, K2CO3/K3Fe(CN)6, t-BuOH/H2O 1:1; iv) Ac2O, pyr; v) NaBH3CN, 
MeCN, CH2O, pH~7; vi) 4 % aq. HF, MeCN; vii) Swern oxidation; viii) cat. KCN, MeOH; 
ix) H2, Pd/C, MeOH. 
 
Recently, Ruiz et al. reported the amino acid based synthesis of D-fucosamine 27 
(Scheme 3) and its N-methyl derivative 17 (Scheme 4).31 The key intermediate 20 was 
constructed by a syn-aldol type reaction between Schöllkopf's bislactim ether 18, prepared 
from glycine and L-valine, and the L-threonine derived 1,3-dioxolane-4-carboxaldehyde 
19. Benzyl protection of the intermediate 20, followed by selective hydrolysis of the 
pyrazine moiety afforded the amino ester 22. At this point, the synthesis routes for the two 
fucosamine derivatives 27 and 17 were differentiated, due to the introduction of the N-
methyl functionality to the latter one. 
Preparation of D-fucosamine 27 proceeded via Cbz-protection of the amino group of 22, 
followed by acidic cleavage of the acetonide, thus generating the desired lactone 24. After 
24 
O-silylation of 24, the fully protected lactone 25 was reduced to a mixture lactols 26, 
which upon acidic deprotection furnished D-fucosamine 27. 
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Scheme 3. i) NaH, BnBr, NBu4I, THF, rt; ii) HCl, EtOH, rt; iii) Na2CO3, NaHCO3, CbzCl, 
dioxane/H2O 1:1, rt; iv) TFA/THF/H2O 6:6:1, rt; v) iPrMe2SiCl, imidazole, THF, rt; vi) 
DIBAL-H, -78 °C, toluene/THF 2:1; vii) H2, Pd/C, MeOH/HCl 2:1, rt, Dowex, aq. NH3. 
 
For the preparation of N-methyl derivative 17, the N-methyl moiety was brought to the 
molecule at the amino ester stage (Scheme 4). Treatment of the amino ester 22 with 
diphenylketimine and a catalytic amount of p-toluenesulfonic acid produced the imino 
ester 28. Acidic reduction of the imine 28 to a secondary amine, followed by subsequent 
reductive methylation provided the monomethylamine 29, which was converted to the 
target N-methyl-D-fucosamine 17 via similar transformations as performed for compound 
23 in Scheme 3. 
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Scheme 4. i) Ph2CNH, PTSA (cat.), CH2Cl2, rt; ii) NaBH3CN, H2CO, HOAc (gl.), pH~7, 
MeCN; iii) TFA/THF/H2O 6:6:1, rt; iv) iPrMe2SiCl, imidazole, THF, rt; v) DIBAL-H, -78 
°C, toluene/THF 2:1; vi) H2, Pd/C, MeOH/HCl 2:1, rt, then Dowex, aq. NH3. 
 
2.1.3. Elsaminose 
 
Ruiz et al. utilized the key intermediate 20 as described for the preparation of the 
fucosamine derivatives 27 and 17 also in the synthesis of elsaminose 39 (Scheme 5),31b,32 
which is the amino sugar constituent of the antitumor antibiotic elsamicin A. The amino 
sugar moiety makes elsamicin A remarkably water soluble and seems to have a critical 
role in the regulation of the biological activity of elsamicin A.33 
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Figure 4. Elsamicin A. 
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The synthesis of elsaminose followed a similar pattern as reported above for the 
fucosamine derivatives 27 and 17. Methylation of the free hydroxyl group of the key 
intermediate 20, followed by removal of the chiral auxiliary gave the amino ester 34, 
which upon Cbz- protection and cyclization in acidic media provided lactone 36. O-
Silylation of 36, followed by DIBAL-H reduction afforded a mixture of furanoses 38, 
which after final deprotection produced elsaminose 39. 
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Scheme 5. i) NaH, MeI, THF, 0 °C → rt; ii) 0.25 N HCl, EtOH, rt; iii) Na2CO3, NaHCO3, 
CbzCl, dioxane/H2O 1:1, rt; iv) TFA:THF:H2O 6:6:1, rt; v) iPrMe2SiCl, imidazole, THF, 
rt; vi) DIBAL-H, -78 °C, toluene:THF 2:1; vii) H2, Pd/C, then Dowex 50x8-200, then HCl. 
 
2.1.4. Dideoxygulopyranoside 
 
In our group, methyl 4-amino-4,6-dideoxygulopyranoside 45 was synthesized from the L-
threonine derived aldehyde 40 (Scheme 6).34 The aldehyde 40 was subjected to a modified 
Horner-Wadsworth-Emmons olefination, producing Z-enoate 41 in very high yield and 
excellent selectivity (Z:E ratio 17:1). Simultaneous cleavage of the acetonide with 
cyclization in glacial acetic acid produced lactone 42. Osmium-catalyzed cis-
dihydroxylation afforded stereoselectively diol 43, which was converted to the target 
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methyl glycoside 45 via DIBAL-H reduction and subsequent acidic methanolysis in 29 % 
overall yield from aldehyde 40. 
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Scheme 6. i) MeO2CCH2P(O)(OCH2CF3)2, K2CO3, 18-crown-6; toluene, -20 °C → rt; ii) 
AcOH, 60 °C; iii) OsO4, NMO, t-BuOH/H2O/acetone; iv) DIBAL-H, toluene, followed by 
CSA, MeOH. 
 
2.2. Monoamino trideoxyhexoses 
 
2.2.1. Daunosamine 
 
Daunomycin (or daunorubicin) and adriamycin are anthracycline anticancer antibiotics 
which both contain an amino sugar fragment L-daunosamine.35 L-Daunosamine derivatives 
have been synthesized from amino acids by several groups. 
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Figure 5. Daunomycin: R = H, adriamycin: R = OH. 
 
In 1979, Fuganti and co-workers reported the synthesis of D-3-epi-daunosamine 
derivative 53 by utilizing the chirality of L-threonine (Scheme 7).36 L-Threonine was 
converted to ester 48 via deamination, esterification and ketalization. Reduction of 48 by 
lithium aluminun hydride to the corresponding alcohol, followed by oxidation with 
pyridinium chlorochromate gave aldehyde 50, which upon Wittig reaction produced the 
α,β-unsaturated ester 51. Stereospecific addition of ammonia to the double bond and 
acidic hydrolysis of the dioxolane ring, followed by benzoylation resulted in the formation 
of lactone 52. Reduction of lactone to lactol furnished N-benzoyl-D-3-epi-daunosamine 53.  
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Scheme 7. i) HNO2; ii) MeOH, HCl; iii) DMP, PTSA (45 % overall); iv) LiAlH4, Et2O (85 
%); v) PCC, CH2Cl2, AcONa, vi) Ph3P=CHCO2Et, vii) NH3, MeOH; viii) 2N HCl; ix) 
BzCl, pyr/CH2Cl2; x) DIBAL-H, THF. 
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In 1981, Fuganti and co-workers prepared N-benzoyl-L-daunosamine 58 starting from 
D-threonine (Scheme 8).37 D-Threonine was first converted to the dioxolane derivative 54, 
which upon addition of a Grignard reagent gave an inseparable 4:1 mixture of epimeric 
alcohols 55 with the syn-isomer predominating. Transformation of the alcohol 
intermediates 55 to the azide derivatives 56 proceeded via tosylation with inversion of 
configuration, producing a 1:4 mixture of syn- and anti-isomers. Successive reduction, 
deketalization and benzoylation led to the formation of the N-benzoylated isomers 57, 
which were separated by crystallization. Ozonolysis of 57a, followed by treatment with 
dimethyl sulfide provided N-benzoyl-L-daunosamine 58. 
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Scheme 8. i) NaNO2, H2SO4; ii) MeOH, H3O+; iii) cyclohexanone, PTSA; iv) 
NaAlH2(OCH2CH2OMe)2, Et2O, -50°C; v) CH2=CHCH2MgBr, THF, -78 °C; vi) pTsCl, 
pyridine; vii) NaN3, NH4Cl, DMF, 100 °C, viii) LiAlH4, Et2O; ix) 50 % AcOH, x) BzCl, 
K2CO3, acetone; xi) O3, MeOH, -20 °C, then Me2S. 
 
Jurczak et al. have utilized the chirality of L-homoserinal derivative 59, obtained from 
L-aspartic acid, in the synthesis of L-daunosamine (Scheme 9).38 To start with, L-aspartic 
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acid was converted to lactone 59, which upon transesterification and subsequent formation 
of the silyl ether afforded compound 60. After replacement of the Cbz-protection of the 
amine by a BOC-group, reduction of the ester functionality to primary alcohol, followed 
by benzyl protection provided intermediate 61. Removal of the silyl protection and 
oxidation of the resulting free hydroxy group generated L-homoserinal derivative 63. 
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Scheme 9. i) DCC, MeOH, rt; ii) TBSCl, imidazole, DMF, 40 °C; iii) H2, 5 % Pd/C, 
(BOC)2O, MeOH, rt; iv) LiAlH4, Et2O, -25 °C; v) BnBr, NaH, DMF, -10 °C; vi) Bu4NF, 
THF, rt; vii) SO3/pyr, DMSO, rt; viii) vinyl-MgCl, Et2O, -78 °C; ix) mCPBA, CH2Cl2, 5 
°C; x) DIBAL-H; Et2O, -78 °C → -40 °C; xi) DMP, acetone, PTSA, 0 °C → 15 °C; xii) 
Na, NH3 (liq.); xiii) HCl/MeOH (pH≈1), rt; xiv) Ac2O, pyr, rt. 
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Treatment of 63 with vinylmagnesium chloride produced the anti-allylalcohol 64 in 
high diastereoselectivity. Epoxidation resulted in the formation of the syn-epoxide 65 as a 
single isomer. Reductive ring opening and subsequent transketalization gave the 
isopropylidene derivative 66. Cleavage of the benzyl protection and oxidation of the 
resulting free alcohol afforded aldehyde 68. Treatment of aldehyde 68 with acidic 
methanol, followed by acetylation afforded the target L-daunosamine derivative 69 as a 
95:5 mixture of methyl α- and β-glycosides. 
Another L-homoserinal based approach for the synthesis of daunosamine derivative was 
reported by Konradi and Pedersen.39 They prepared N-benzoyl-D-3-epi-daunosamine 53 
starting from commercially available N-Cbz-L-aspartic acid 70 (Scheme 10). The key step 
of the synthesis was pinacol cross-coupling between the α-amino aldehyde and an 
aliphatic aldehyde. 
The synthesis started by conversion of N-Cbz-L-aspartic acid 70 into the lactone 59, 
which upon DIBAL-H reduction to lactol and subsequent ring opening by 1,2-
ethanedithiol in acidic media produced the hydroxydithiolane 71. Oxidation of 71 gave the 
α-amino aldehyde 72. Pinacol coupling of 72 with an excess of acetaldehyde in the 
presence of a vanadium(II) reagent [V2-Cl3(THF)6]2[Zn2Cl6] afforded the cross-coupled 
product 73 as the major isomer. Cleavage of the dithiolane protection provided an 
anomeric mixture of methyl N-Cbz-D-furanosides 74, which was converted to N-benzoyl-
D-3-epi-daunosamine 53 in 13 % overall yield from N-Cbz-L-aspartic acid 70. 
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Scheme 10. i) DIBAL-H; CH2Cl2, -78 °C; ii) (CH2SH)2, BF3(Et2O), CH2Cl2; iii) SO3(py), 
DMSO, Et3N; iv) MeCHO, [V2-Cl3(THF)6]2[Zn2Cl6], CH2Cl2, 0 °C; v) Hg(ClO4)2(H2O)3, 
MeOH; vi) LiOH, MeOH/H2O, reflux; vii) PhCOCl, K2CO3; H2O; viii) 20 % AcOH/H2O, 
reflux. 
 
2.2.2. Hollantosamine 
 
Guanti et al. have synthesized the hollantosamine derivative 81 from L-allo-threonine 
synthetic equivalent 75 by a 14 step sequence in 8 % overall yield. (Scheme 11).40 The L-
allo-threonine derivative 75 was first converted to the aldehyde 76 in three steps, which 
upon condensation with the lithium enolate of benzyl acetate afforded the anti-alcohol 77 
in excellent stereoselection. Reduction of the ester to a primary alcohol with calcium 
borohydride, followed by selective protection of the hydroxyl group produced compound 
78, which was converted to the triacetate 79 in three steps. A series of protecting group 
interchanges provided acetonide 80. Oxidation of the free alcohol group to aldehyde and 
subsequent hydrolysis of the ketal generated the N-acetylhollantosamine 81, which was 
characterized as its triacetyl derivative 82. 
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Scheme 11. i) CH2=C(OLi)OBn, THF, -87 °C; ii) Ca(BH4)2, EtOH, THF; iii) 4-
MeOC6H4OH, Ph3P, DEAD; iv) AcOH/1N HCl 2:1, 75 °C; v) H2, PtO2, EtOH-H2O; vi) 
Ac2O, pyr, rt; vii) Et3N, MeOH, reflux; viii) MeOC(Me)=CH2, PTSA, CH2Cl2, rt; ix) 
(NH4)2Ce(NO3)6, H2O, MeCN, pyr; x) TPAP, NMO, 4Å molecular sieves, CH2Cl2, rt; xi) 
AcOH, H2O. 
 
2.2.3. Kedarosamine 
 
Kihlberg et al. have reported a D-threonine based diastereoselective synthesis of 
kedarosamine (Scheme 12), an amino sugar moiety of the enediyne antitumor antibiotic 
kedarcidin chromophore.41 
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Figure 6. Kedarcidin chromophore. 
 
Kedarosamine derivatives 89a and 89b were synthesized from Fmoc- or Cbz-protected 
D-threonine derivatives 83a or 83b. The synthesis route was originally developed for the 
Fmoc-protected derivative 89a,41a which was transformed to kedarosamine 91, whereas the 
use of a Cbz instead of a Fmoc-protection was later found essential for the successful 
preparation of an analogue of kedarcidin chromophore.41b Ketal protection of the hydroxyl 
and amino functionalities of 83 provided the acid 84, which was transformed to the 
Weinreb amide 85 via acid chloride. Addition of allylmagnesium bromide to amide 85 
provided the ketone 86, which upon successive removal of the isopropylidene protection 
and reduction afforded the anti-alcohol 88 as a single diastereomer. Ozonolysis of 88 gave 
the hemiacetal 89. Acidic methanolysis of 89a produced a 4:1 mixture of α- and β-methyl 
glycosides from which the α- anomer 90 was isolated in 60 % yield. Deprotection and 
reductive dimethylation of the resulting amine finally gave methyl α-kedarosamine 91. 
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Scheme 12. i) CH2(OMe)2, PTSA, benzene, reflux; ii) cyanuric chloride, pyr, CH2Cl2; iii) 
Me(MeO)NH.HCl, pyr, CH2Cl2; iv) allyl-MgBr, THF, -78 °C; v) TFA/MeOH 9/1; vi) 
Me4NBH(OAc)3, MeCN/HOAc 1/1, -28 °C; vii) O3, Me2S, MeOH, -78 °C, viii) PTSA, 
MeOH; ix) Pd/C, Pd(OAc)2, NH4HCO2, MeOH; x) 10 % Pd/C, H2, HCHO, MeOH/H2O 
1/1. 
 
2.3. Monoamino tetradeoxyhexoses 
 
2.3.1. Tolyposamine 
 
Guanti and co-workers also reported the synthesis of N-acetylated-L-tolyposamine 98, 
starting from L-allo-threonine derivative.42,43 L-Tolyposamine is the carbohydrate 
component of antibiotic tolypomycin Y, linked by an imine group to the quinone ring. 
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Figure 7. Tolypomycin Y. 
 
The preparation of the target amino sugar 98, starting from the L-allo-threonine 
equivalent 75, could be accomplished either via acyclic 92 (Scheme 13) or cyclic 76 
(Scheme 14) aldehyde intermediates. The acyclic synthetic sequence started by 
transformation of compound 75 into aldehyde 92, having its hydroxyl group protected as 
silyl ether. Wittig reaction of 92 with stabilized phosphorane afforded the unsaturated ester 
93, which was converted into alcohol 94 by hydrogenation of the double bond, followed 
by reduction of the ester functionality. PMP-protection of the free hydroxyl group afforded 
intermediate 95, which upon replacement of the silyl ether and BOC-protections by 
acetates gave compound 96. Cleavage of the PMP-group produced the primary alcohol 97, 
which was transformed to the target N-acetyl-L-tolyposamine 98 via oxidation and 
selective deacetylation in 16 % overall yield from 75. 
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Scheme 13. i) Ph3P=CHCO2Et, toluene, 4Å molecular sieves, 70 °C; ii) H2, PtO2, EtOH, 
rt; iii) Ca(BH4)2, EtOH, THF, -20 °C → rt; iv) pMeOC6H4OH, Ph3P, DEAD, CH2Cl2, rt; v) 
AcOH/1N HCl 2:1, 70 °C; vi) H2, PtO2, EtOH-H2O; vii) Ac2O, pyr, DMAP, rt; viii) 
(NH4)2Ce(NO3)6, H2O, MeCN, pyr, 0 °C; ix) (n-Pr)4NRuO4, NMO, CH2Cl2, 4Å molecular 
sieves, rt; x) DBU, MeOH, 70 °C. 
 
An attempt to convert the cyclic aldehyde intermediate 76 to the unsaturated ester 99 by 
the Wittig condensation resulted in epimerization to the undesired trans isomer 100. Thus, 
by a modified procedure of the HWE olefination the cis- and trans-diastereomers 99 and 
100 were generated in a 95:5 ratio, respectively. The rest of the synthesis followed similar 
transformations as performed for compound 93. 
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Scheme 14. i) (EtO)2P(O)CH2CO2Et, EtN(iPr)2, LiCl, rt, MeCN; ii) H2, PtO2, EtOH, rt; iii) 
Ca(BH4)2, EtOH, THF, -20 °C → rt; iv) pMeOC6H4OH, Ph3P, DEAD, CH2Cl2, rt; v) 
AcOH/1N HCl 2:1; vi) H2, PtO2, EtOH-H2O; vii) Ac2O, pyr, DMAP, rt. 
 
The L-threonine based synthesis route developed for the dideoxy aminohexoses in our 
group could be adapted also for the preparation of epi-tolyposamine 105 (Scheme 15).34 
Standard Horner-Wadsworth-Emmons olefination of aldehyde 40 gave the E-enoate 101 as 
a 4:1 mixture of E- and Z-isomers, respectively. Hydrogenation of the mixture of double 
bond isomers followed by lactonization under acidic conditions afforded compound 103, 
which upon reduction and subsequent acidic methanolysis produced the epi-tolyposamine 
derivative 105 in only five steps and with 42 % overall yield. 
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Scheme 15. i) MeO2CCH2P(O)(OMe3)2, K2CO3, toluene; ii) H2, Pd/C, EtOAc; iii) AcOH, 
60°C; iv) DIBAL-H, toluene, -78 °C; v) MeOH, H+, HC(OMe)3. 
 
2.4. Miscellaneous deoxyaminohexoses 
 
2.4.1. Sibirosamine 
 
Rapoport and co-workers44 utilized L-allo-threonine as the chiral educt in the synthesis of 
methyl L-sibirosaminide 116 (Scheme 16). Sibirosamine is the amino sugar constituent of 
the potent antitumor antibiotic sibiromycin (Fig. 8).45 
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Figure 8. Sibiromycin. 
 
L-allo-Threonine was first protected as its N-phenylsulfonyl derivative 106 and then 
converted to methyl ketone 107 via lithiation, followed by treatment with 
methylmagnesium iodide. The ketone 107 was then reacted with vinylmagnesium bromide 
40 
to afford the tertiary alcohol 108, which was N-methylated with methyl iodide and 
potassium carbonate in isopropanol to give intermediate 109. Osmium-catalyzed 
dihydroxylation of 109 produced a 1:4 mixture of tetraols 110 and 111, which were 
separated by chromatography.  
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Scheme 16. i) PhSO2Cl, Na2CO3; ii) MeLi, -78 °C → 0 °C; iii) MeMgI, 35 °C; iv) 
CH2=CHMgBr, -10 °C → rt; v) K2CO3, MeI, IPA, 65 °C; vi) NMO, OsO4; vii) O2, Pt, 60 
°C; viii) DIBAL-H, -45 °C; ix) MeOH, H+; x) Na, NH3; xi) 6N HCl. 
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Platinum-catalyzed oxidation of the primary hydroxyl group of 111 afforded lactone 112, 
which was reduced by diisobutylaluminium hydride to the anomeric mixture of lactols 
113. Acidic methanolysis of 113, followed by reductive cleavage of the phenylsulfonyl 
group with sodium in liquid ammonia gave a single anomer of methyl L-sibirosaminide 
115. Acidolysis of 115 resulted in the formation of the desired free amino sugar 116, but 
the product was too unstable to be isolated. 
 
2.4.2. Purpurosamine 
 
Kamiyama, Ohno and co-workers have reported the synthesis of 6-epi-D-purpurosamine B 
127 (Scheme 17),46 a component of an aminoglycoside antibiotic fortimicin A,47 starting 
from L-alanine and malic acid. 
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Figure 9. Fortimicin A. 
 
Cbz-protected L-alaninal 117 and the phosphonium salt 118, derived from malic acid, 
were first coupled to form the Z-olefin 119. After benzyl protection of the carbamate 
nitrogen, iodocyclocarbamation was carried out to form the trans cyclocarbamate 121 as 
the sole product. Successive removal of the iodo group and the acetonide moiety afforded 
the diol 123. After selective benzoylation of the primary hydroxyl group, the secondary 
hydroxyl functionality was replaced by azide with inversion of configuration to produce 
the azidocarbamate 125. After transformation of 125 to diol 126, selective oxidation for 
the primary hydroxyl moiety was accomplished by reaction with RuCl2(PPh3)3 -complex 
to generate the protected 6-epi-D-purpurosamine B 127, which was analyzed as its α-
acetoxy derivative 128. 
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Scheme 17. i) KH, THF, 0 °C; ii) BnBr, NaH, DMF; iii) I2, CH2Cl2, 0 °C; iv) n-Bu3SnH, 
benzene; v) 1N HCl, THF; vi) BzCl, Et3N, CH2Cl2; vii) MsCl, Et3N, CH2Cl2; viii) NaN3, 
DMF; ix) Ba(OH)2, dioxane/H2O; x) H2/Pd(OH)2, MeOH/2N HCl; xi) CbzCl, Na2CO3, 
dioxane/H2O; xii) RuCl2.(PPh3)3; xiii) Ac2O, pyr. 
 
Another route to 6-epi-D-purpurosamine B derivative 135, also starting from L-alanine, 
was reported by Jurczak et al. (Scheme 18).48 Addition of diene 130 to BOC-protected L-
alaninal 129 under high pressure resulted in the formation of a mixture of four 
diastereomers (two cis- and two trans-adducts), which upon acid catalyzed isomerization, 
followed by chromatographic separation afforded a 2:1 mixture of thermodynamically 
more stable trans-cycloadducts 131 and 132. Successive hydroboration of adduct 131 by 
thexyl borane and oxidative work-up gave alcohol 133. Oxidation of 133 to the 
corresponding ketone, followed by reaction with hydroxylamine and subsequent 
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acetylation yielded a 1:1 syn-anti mixture of oxime acetates 134. Final reduction, acidic 
hydrolysis and acetylation provided methyl 2,6-di-N-acetyl-6-epi-α-D-purpurosaminide B 
135 and its 2-epimer in a ratio of 6:1. The pure 6-epi-D-purpurosamine B 135 was obtained 
by recrystallization. 
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Scheme 18. i) 20 kbar, 2 % Eu(fod)3, Et2O, 50 °C; ii) PPTS, MeOH, rt; iii) ThxBH2.DMS, 
Et2O, -20 °C; iv) 30 % H2O2, 30 % NaOH aq.; v) PCC, 4Å molecular sieves, CH2Cl2, rt; 
vi) NH2OH.HCl, K2CO3, MeOH, rt; vii) Ac2O, Et3N, DMAP, CH2Cl2, rt; viii) BH3.THF, 
THF, -78 °C → rt; ix) TFA, rt. 
 
Jurczak et al. have applied the methodology described above also to the syntheses of 
purpurosamine B49 in enantiomerically pure form and purpurosamine C50 in racemic form. 
 
2.4.3. Destomic acid 
 
Marshall and Beaudoin have used L-serine as the chiral auxiliary in the synthesis of the 
precursor of destomic acid,51 a component of the destomycin52 and hygromycin53 
antibiotics (Scheme 19). The synthesis of the protected destomic acid 149 started from N-
Cbz-protected L-serine 136, which was transformed to the corresponding aldehyde 139 via 
standard esterification, ketal protection and DIBAL-H reduction. Horner-Emmons reaction 
with triethyl phosphonoacetate afforded the E-enoate 140, which was converted to enal 
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142 via successive reduction and Swern oxidation. Addition of the (R)-silyloxy allylic 
stannane 143 to 142 produced the syn-adduct 144 as the sole diastereomer, which after 
silylation was subjected to osmium-catalyzed bisdihydroxylation to form tetrol 146. 
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Scheme 19. i) SOCl2, MeOH, 0°C → rt (95 %); ii) DMP, BF3.OEt2, rt (95 %); iii) DIBAL-
H, toluene, -78 °C (75 %); iv) (EtO)2POCH2CO2Et, NaH, THF, 0 °C (79 %); v) DIBAL-
H/hexanes, THF, -78 °C→ rt (79 %); vi) DMSO, Et3N, CH2Cl2, -78 °C → 0 °C (90 %); 
vii) 143, BF3.OEt2, CH2Cl2 (87 %); viii) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C (97 %); ix) 
NMO, acetone, H2O, OsO4/t-BuOH (68 %); x) H5IO6, THF, 0 °C (81 %); xi) TBAF, THF 
(86 %); xii) AcOH/H2O 9:1, 50 °C (97 %); xiii) CuSO4, H2SO4, acetone (46 %). 
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Selective oxidative cleavage of 146 gave lactol 147. Removal of the silyl protection and 
acetonide hydrolysis offered the pyranose derivative 149, which is a precursor of the 
destomic acid. For characterization, the sugar derivative 149 was converted to a known 
bis-acetonide 150 along with the formation of by-product 151. 
Another L-serine based synthesis for the destomic acid was reported by Jurczak et al. 
(Scheme 20).54 Hetero-Diels-Alder cycloaddition of the Danishefsky-type diene 153 to L-
serinal derivative 152 afforded pyrone 154 as the major product, which was separated from 
the other diastereomers by flash chromatography. Luche reduction of the carbonyl moiety 
gave intermediate 155, which upon osmium-catalyzed dihydroxylation, followed by 
debenzoylation and ketal protection of the tetrol produced the diacetonide 156. Removal of 
the silyl protection provided the protected precursor 157 of destomic acid. 
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Scheme 20. i) ZnBr2, THF; ii) TFA, CH2Cl2; iii) NaBH4, CeCl3.7H2O, MeOH; iv) OsO4, 
NMO, THF-H2O; v) K2CO3, MeOH; vi) DMP, PTSA, acetone; vii) n-Bu4NF, THF; viii) 
Ref. 55. 
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2.4.4. Lincosamine 
 
Szechner and Achmatowicz have reported a D-allo-threonine based synthesis of methyl-α-
D-lincosaminide 169 (Scheme 21),56 which is the amino sugar component of a Gram-
positive glycopeptide antibiotic lincomycin. 
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Figure 10. Lincomycin. 
 
D-allo-Threonine was first converted to D-allo-threoninal 158 following known 
procedures. Addition of furyllithium 159 to the aldehyde 158 produced the anti- and syn-
alcohols 160 and 161 in a ratio of 55:45, respectively. After purification by flash 
chromatography, the desired anti-alcohol 160 was oxidized and then methylated to form 
the methyl α-uloside 163. Reduction of the carbonyl group of 163 afforded the threo 
alcohol 164, which upon epoxidation and successive acetylation gave exclusively the gulo 
epoxide 166. Opening of the epoxide and cleavage of the isopropylidene group under 
acidic reaction conditions followed by acetylation provided intermediate 167. Removal of 
the N-benzenesulfonyl group and subsequent acetate protection accomplished methyl 
N,2,3,4,7-pentaacetyl-α-D-lincosaminide 169 in 20 % overall yield from 158. 
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Scheme 21. i) THF/hexane, Et2O, -70 °C; ii) mCPBA, CH2Cl2, rt; iii) MeI, Ag2O, Et2O, rt; 
iv) NaBH4, CeCl3, rt; v) 60 % H2O2, MeCN, rt; vi) Ac2O, pyr, DMAP; vii) HClO4, H2O, 
THF, 40 °C; viii) Na, NH3, -70 °C → rt. 
 
Marshall and Beaudoin have used a similar approach for the synthesis of lincosaminide 
derivative 184 from D-threonine as described for the preparation of the destomic acid 
derivative 150 from L-serine in Section 2.4.3. (Scheme 22).51 Horner-Emmons reaction of 
N-BOC-threoninal 170 produced the E-enoate 171, which was converted to enal 173 via 
successive DIBAL-H reduction and Swern oxidation. Introduction of the (R)-silyloxy 
allylic stannane 143 generated the syn-adduct 174, which after TBS-protection was 
bisdihydroxylated to form tetrol 176. Lactol 177 was obtained by oxidative cleavage of 
176 and transformed to a mixture of acetonides 179 and 180 after deketalization. The 
former acetonide was converted to the latter one under acidic conditions. 
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Scheme 22. i) (EtO)2POCH2CO2Et, NaH, THF, 0 °C; ii) DIBAL-H/hexanes, THF, -78 °C; 
iii) DMSO, Et3N, CH2Cl2, -78 °C → 0 °C; iv) 143, BF3.OEt2, CH2Cl2; v) TBSOTf, 2,6-
lutidine, CH2Cl2, 0 °C; vi) NMO, OsO4, H2O, vii) H5IO6, THF, 0 °C; viii) TBAF, THF, 
HOAc, H2O; ix) acetone, CuSO4, H2SO4; x) PTSA, MeOH; xi) p-nitrobenzoic acid, Ph3P, 
DEAD, benzene; xii) KCN, MeOH; xiii) TFA, CH2Cl2; xiv) Ac2O, MeOH, pyr. 
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The required inversion of configuration for the hydroxyl group at the C7-position was 
achieved by Mitsunobu methodology. Finally, removal of the p-nitrobenzoic acid moiety 
and the BOC-protection, followed by acetylation provided the target acetamide 184. 
 
2.4.5. Galantinic acid 
 
Ohfune and Sakai reported in 1990 the first total synthesis of galantinic acid 197, starting 
from the readily available L-serinal derivative 185 (Scheme 23).57 Galantinic acid is an 
amino acid constituent in a peptide antibiotic galantin I, isolated from a culture broth of 
Bacillus pulvifaciens.58 
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Figure 11. Galantin I. 
 
The first step of the synthesis was the conversion of the fully protected L-serinal 18559 
to the corresponding Z-allyl alcohol 187 via standard procedures. Epoxidation of 187 with 
mCPBA afforded the syn-epoxy alcohol 188 exclusively, which was transformed to a 2:1 
mixture of E and Z unsaturated epoxy esters 189 via Swern oxidation and subsequent 
Wittig olefination. Reduction of the oxirane ring was performed by employing Miyashita's 
reagent60 to produce the E β,γ-ester 190 as a single regioisomer. Cyclization of 190 by 
DBU generated the unsaturated lactone 191, which upon successive epoxidation and 
reduction was converted to (3R)-hydroxy lactone 193. Since the natural isomer has (3S)-
configuration, inversion of configuration for the hydroxyl group of compound 193 was 
carried out. Oxidation of the hydroxyl group at C3 to the corresponding ketone, followed 
by immediate reduction provided a 3:1 mixture of stereoisomers (3S)-195 and (3R)-193, 
respectively. After silyl protection, the stereoisomers were chromatographically separated 
and the desired (3S)-silyl ether 196 was converted to the target (-)-galantinic acid 197 
under acidic conditions. 
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Scheme 23. i) (CF3CH2O)2P(O)CH2CO2Me, NaH, 18-crown-6, THF, -78 °C; ii) DIBAL-
H, BF3.OEt2, CH2Cl2, -78 °C; iii) mCPBA, CH2Cl2, 0 °C; iv) (COCl)2, DMSO, CH2Cl2, -
90 °C, then Et3N; v) Ph3P=CHCO2Me, benzene rt; vi) Na+[PhSeB(OEt)3]-, EtOH, rt; vii) 
DBU, benzene, reflux; viii) t-BuOOH, Triton B (cat.), THF, 0 °C; ix) PhSeH, IPA, rt; x) 
TFAA, DMSO, CH2Cl2, -78 °C, then Et3N, -78 °C; xi) NH3.BH3, citric acid, THF/H2O 
10:1, rt; xii) TBSOTf, 2,6-lutidine, CH2Cl2, -78 °C; xiii) TFA, CH2Cl2, rt, then Dowex 
50Wx4 (elution with 1N NH3). 
 
Recently, another L-serine based synthesis of galantinic acid was reported with 
improved stereoselectivity (Scheme 24).61 Conversion of L-serine to the N,O-protected 
aminodiol 198 by a known procedure,62 followed by Swern oxidation and in situ reaction 
of the resulting aldehyde with allylmagnesium bromide produced the syn-1,2-amino 
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alcohol 199 in excellent stereoselectivity (syn:anti > 95:5). After ketal protection, 
Lemieux-Johnson oxidative cleavage of the double bond yielded the corresponding 
aldehyde 201. Treatment of 201 with bromozincacetate resulted in the formation of the 
hydroxyester 202 as a 3:2 mixture of diastereomers, which upon oxidation with pyridinium 
dichromate afforded ketone 203. Cleavage of the acetonide protection afforded the β-
hydroxy ketone 204, which was stereoselectively reduced to the anti-diol 205 by the 
Saksena-Evans protocol.63 Desilylation of the primary alcohol group accomplished the 
galantinic acid derivative 206 in 16 % overall yield. 
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Scheme 24. i) Swern oxidation, then H2C=CHCH2MgBr; ii) Me2C(OMe)2, PPTS; iii) 
OsO4, NMO, then NaIO4; iv) BrZnCH2CO2Et, Et2O; v) PDC, CH2Cl2; vi) 80 % AcOH; vii) 
NaB(OAc)3H, MeCN, AcOH, -20 °C; viii) Bu4NF, THF. 
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3. Pradimicin syntheses in the literature 
 
This chapter introduces the published synthetic approaches to pradimicin. The pradimicin 
antibiotic has not been synthesized yet, and there exists only one total synthesis of 
pradimicinone, the aglycon of the pradimicin-benanomicin antibiotics (Fig. 12).64 The 
syntheses of the aromatic aglycon and the disaccharide moiety of pradimicin will be 
presented first and the glycosylation study between the disaccharide donor and the 
aromatic acceptor will be discussed at the end of this chapter. 
Chapter 4 will present my own work concerning the L-threonine based synthesis of the 
disaccharide fragment of pradimicin A, and Chapter 5 will give the full experimental data 
of the products prepared in this thesis. 
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Figure 12.   R2 = NHME: pradimicin A  
R2 = NH2: pradimicin C, benanomicin B 
R2 = OH: benanomicin A 
 
   R1 = H: pradimicinone, benanomicinone 
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3.1. Synthesis of the aromatic aglycon of pradimicin 
 
3.1.1. Suzuki 
 
The synthesis of benzo[a]naphthacene natural products has been of keen interest by 
several groups,64-68 but there exists only one total synthesis of the aglycon of the 
pradimicin-benanomicin antibiotics, reported by Suzuki et al.64 Pradimicinone consists of 
a D-alanine moiety and a pentacycle, whose rings are named A-E (see Fig. 12). The first 
step in the synthesis of the aglycon part was the preparation of the A and CD rings. The B 
ring was created by combining the A and CD rings to form the tetracyclic structure of A-
D. The final steps were the introduction of the E ring moiety to the tetracycle by a Diels-
Alder reaction and final attachment of the of the D-alanine functionality by condensation. 
The preparation of the A ring 212 started by conversion of the orsellinic acid derivative 
207 into the triflate 208 in three steps (Scheme 25). Carbonylation and subsequent 
selective reduction by NaBH4 generated the primary alcohol, which was protected to 
produce the bis-MOM ether 210.  
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Scheme 25. Synthesis of the A ring fragment: i) MOMCl, iPr2NEt, CH2Cl2, 40 °C; ii) H2, 
Pd(OH)2, EtOAc; iii) Tf2O, iPr2NEt, CH2Cl2, -78 °C; iv) CO, PhOH, Et3N, Pd(OAc)2, 
dppf/DMF, 60-80 °C; v) NaBH4, 1,4-dioxane, MeOH, 0 °C → rt; vi) MOMCl, iPr2NEt, 
CH2Cl2; vii) TFA, CH2Cl2, 0 °C; viii) I2, Hg(OAc)2, CH2Cl2, 0 °C. 
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Selective deprotection in acidic media, followed by iodination afforded the required A ring 
fragment iodophenol 212 in 71 % overall yield. 
In the synthesis of the CD ring fragment 219, the known compound 213 was first 
regioselectively hydroxymethylated and then O-methylated affording the benzyl alcohol 
214 (Scheme 26). Oxidation of 214 to the corresponding aldehyde 215, followed by HWE 
olefination with 216 provided the unsaturated ester, which after hydrolysis of its tert-butyl 
moiety gave the unsaturated acid 217. Cyclization with acetic anhydride/sodium acetate 
led to naphthyl acetate 218, which after deacetylation provided the desired naphthol 219 in 
54 % overall yield. 
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Scheme 26. Synthesis of the CD ring fragment: i) (HCHO)n, Me2AlCl, CH2Cl2, 0 °C; ii) 
MeI, K2CO3, acetone, reflux; iii) MnO2, CH2Cl2, 0 °C; iv) NaH, THF; v) TFA, H2O; vi) 
Ac2O, NaOAc, reflux; vii) NaOH (aq), THF, EtOH, 70 °C, H3O+. 
 
In the next stage the A and CD rings were connected via an ester formation using water-
soluble carbodiimide as the condensing agent (Scheme 27). Palladium-catalyzed internal 
cyclization accomplished the tetracyclic intermediate 221, which after reduction and 
cleavage of the MOM-protection gave alcohol 223. After silylation of the primary 
hydroxyl groups, the enantiomers were resolved by conversion to (-)-(1S,4R)-camphanoyl 
esters, generating a 1:1 mixture of diastereomers 225a and 225b which were separated by 
55 
flash chromatography. Deprotection of 225a furnished the enantiopure tetraol 226 in 19 % 
yield (from A and CD). 
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Scheme 27. i) EDCI, DMAP, CH2Cl2 (78 %); ii) Pd(OAc)2, PPh3, tBUCO2Na, N,N-
dimethylacetamide, 110 °C; iii) NaBH4, THF, MeOH, -40 °C (2 steps, 86 %); iv) 6M HCl, 
DME, 50 °C (93 %); v) TBSCl, imidazole, DMF (84 %); vi) (-)-(1S,4R)-camphanoyl 
chloride, DMAP, pyr, then SiO2 (225a: 38 %, 225b: 40 %); vii) HF (aq.), MeCN (aq.), 
K2CO3, MeOH (97 % from 225a). 
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The tetraol 226 was converted to dialdehyde 227, which upon reductive cyclization 
with SmI2 produced the enantiomerically pure trans-diol (S,S)-228 exclusively (Scheme 
28). Acetate protection of the diols and subsequent oxidation of the aromatic system 
afforded compound 229, which was connected with siloxydiene 230 via Diels-Alder 
reaction to generate the pentacycle intermediate 231.  
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Scheme 28. Total synthesis of pradimicinone: i) MeI, K2CO3, acetone, 40 °C (81 %); ii) 
MnO2, CH2Cl2 (79 %); iii) SmI2, THF, 0 °C (quant.); iv) Ac2O, DMAP, pyr (quant.); v) 
Ce(NH4)2(NO3)6, MeCN, 0 °C (quant.); vi) THF, 0 °C → rt; SiO2, then, K2CO3, CH2Cl2, 
THF (90 %); vii) BCl3, CH2Cl2, -10 °C (99 %); viii) 2 M NaOH, 70 °C; H3O+; ix) D-Ala-
OMe.HCl, BOP, Et3N, DMF (2 steps, 80 %); x) 0.1 M NaOH, H3O+ (quant.). 
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Selective cleavage of the methyl ether protection, followed by deacetylation gave the fully 
functionalized aromatic skeleton 233, which upon condensation with D-alanine methyl 
ester created the pradimicinone methyl ester 234. Final deprotection of 234 furnished the 
target pradimicin aglycon 235. 
 
3.1.2. Hauser 
 
Recently, Hauser et al. reported a regiospecific synthesis of the benanomicinone/ 
pradimicinone analogue 249 by condensation of the phenylsulfinyl naphthoate 244 with 
the ortho-quinone monoketal 239.65  
The ortho-quinone monoketal 239 was prepared from benzyl ether protected 
isobenzopyranone 236, which was first reacted with lithium enolate of methyl acetate to 
produce the naphthoate 237 (Scheme 29). Etherification of 237, followed by sequential 
hydrogenolysis and oxidation gave the quinone ketal 239. 
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Scheme 29. i) LDA, THF, acetone; ii) (MeO)2SO2, acetone, K2CO3; iii) H2/Pd-C, MeOH 
(98 %); iv) PhI(OAc)2, MeOH (68 %). 
 
The synthesis of ortho-phenylsulfinyl naphthoate 244 started by condensation of the 
anion of sulfone 240 with methyl crotonate, leading to formation of the naphthoate 
dianion, which was in situ methylated to yield a mixture of mono- and dimethylated 
regioisomers (Scheme 30). Additional methylation of the mixture provided the dimethyl 
ether 241, which upon bromination gave the dibrominated product 242. Conversion of 242 
to the corresponding sulfoxide 244 was obtained via thiophenyl methyl ether 243, which 
was oxidized by peroxyboric acid. 
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Scheme 30. i) LiOtBu, THF, methyl crotonate; ii) (MeO)2SO2, K2CO3, acetone; iii) NBS, 
CCl4; iv) KOH, PhSH, MeOH; v) NaBO3.4H2O, AcOH. 
 
The anion sulfoxide 244 and the quinone monoketal 239 were connected by a 
condensation reaction to create the pentacyclic intermediate 245 (Scheme 31). Reductive 
replacement of the aryl bromine proceeded by palladium-catalyzed hydrogenation 
affording compound 246, which upon rapid hydrolysis (less than 15 seconds) offered the 
ortho-quinone 247. Quinone 247 was directly reduced to a diastereomeric mixture of the 
corresponding diols, which after subsequent acetylation produced the trans- and cis-
acetates 248a and 248b in a ratio of 3:1, respectively. After purification by flash 
chromatography, the trans-isomer 248a was oxidized to the target benzo[a]naphthacene-
8,13-quinone 249. 
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Scheme 31. i) tBuLi, THF, DMSO; ii) (MeO)2SO2, acetone, K2CO3 (2 steps, 31 %); iii) 
Pd/C, H2 (97 %); iv) TFA, H2O, CHCl3; v) NaBH4, EtOH; vi) Ac2O, pyr, DMAP (3 steps, 
85 %); vii) Ce(NH4)2(NO3)6, H2O; MeCN (44 %). 
 
3.2. Design of the suitable disaccharide donor 
 
Suzuki et al. have prepared the pradimicin disaccharide fragment 252, in which the NHMe 
functionality was replaced with an azide moiety (Scheme 32).69 The synthesis strategy was 
based on the orthogonal glycosylation methodology,70 by employing the combination of a 
thioglycoside donor and a glycosyl fluoride acceptor, which remain unaffected under the 
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conditions required for the activation of the other. The thioglycosyl donor 250 was derived 
from D-xylose and the fluoride acceptor 251 was prepared from a D-glucose derivative in 8 
steps (Scheme 33). The activation conditions for the glycosyl fluorides are listed in Section 
3.3 and the activators for the thioglycosides will be discussed in Chapter 4. 
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Scheme 32. i) NIS, TfOH (cat.), CH2Cl2, -40 °C, 2 h, 93 % (α:β 1:5), then crystallization 
from EtOH. 
 
The synthesis of the amino sugar acceptor 251 started from the 2,3-diacetylated D-
glucose derivative 253, which was first mesylated at its 4- and 6-positions to give 
compound 254. In the next step, the primary mesylate was selectively displaced by iodine, 
which was subsequently removed by hydrogenolysis in the presence NaOAc buffer to 
produce the 6-deoxy sugar 256. Conversion of 256 to the azide derivative 257 was 
accomplished by treatment with NaN3. After acetylation of 257, the anomeric position of 
258 was fluorinated with HF.pyr complex and the acetate protection was cleaved to give 
the fluoride 259. Benzoyl protection at the 2-position of 259 was carried out 
regioselectively by benzoyl chloride and pyridine, affording an 8:1 mixture of 2-O- and 3-
O-monobenzoates. Finally, crystallization from EtOAc furnished the target 2-O-
benzoylated α-fluoride 251 in 21 % overall yield.  
The thioglycosyl donor 250 was prepared from D-xylose by standard procedures, first 
acetylating the free hydroxyl groups and then introducing the thiophenyl moiety at the 
anomeric position under acidic conditions. 
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Scheme 33. i) MsCl, pyridine; ii) NaI, 2-butanone, reflux; iii) H2, Pd/C, NaOAc, EtOH, 
EtOAc; iv) NaN3, n-Bu4NCl, DMF, 110 °C; v) Ac2O, conc. H2SO4; vi) (HF)n.pyridine, 
CH2Cl2, -20 °C → rt; vii) K2CO3, MeOH, 0 °C; viii) BzCl, pyridine, 0 °C → rt. 
 
The desired pradimicin disaccharide fragment 252 was obtained via NIS/TfOH 
glycosylation.71 Treatment of the thioglycosyl donor 250 and the glycosyl fluoride 
acceptor 251 with NIS and a catalytic amount of TfOH in CH2Cl2 at –40 °C for 2 hours 
afforded a 1:5 mixture of α- and β-glycosylated disaccharides, from which the required β-
glycoside 252 was isolated by crystallization (Scheme 32). 
 
3.3. Glycosylation study 
 
Common activators of glycosyl fluorides include a combination of tin chloride and silver 
perchlorate (SnCl2/AgClO4),72 the use of Lewis acids such as BF3.OEt273 or TMSOTf74 and 
employment of mixtures of the (bis)cyclopentadienyl dichlorides of hafnium or zirconium 
with silver perchlorate or silver triflate e.g. (Cp2HfCl2/AgClO4),75 (Cp2ZrCl2/AgClO4),76 
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(Cp2HfCl2/AgOTf)77 and (Cp2ZrCl2/AgOTf).78 Particularly selective activation has been 
achieved with the methods involving hafnium or zirconium, although the type of protective 
group at the 2-position also plays a significant role in the stereochemical outcome at the 
glycosidic bond: a participating group such as an acetate or a benzoate will produce 
predominantly 1,2-trans-glycosides whereas a non-participating functionality like a benzyl 
group prefers the formation of 1,2-cis glycosidic linkages. 
Suzuki and co-workers have performed some model glycosylation studies for the 
disaccharide 252 and a variety of glycosyl promoters and aromatic acceptors.69 The α/β 
stereoselectivity of the glycosylation of the α-fluoride donor 252 with several promoters 
were examined first, employing benzyl alcohol as the model glycosyl acceptor (Scheme 
34). The results of these experiments are presented in Table 1. 
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Scheme 34. i) Reaction conditions: 1 eq. of donor 252, 1.4 eq. of acceptor BnOH, CH2Cl2. 
 
The glycosylation attempts of the disaccharide 252 with BnOH employing Lewis acids 
(BF3.OEt2 or TMSOTf) resulted in complete recovery of the starting material (Entries 1 
and 2). The use of the traditional SnCl2/AgClO4 activation procedure resulted in selective 
β-glycosylation but with a low yield (Entry 3). Excellent results were obtained with the 
zirconium- and hafnium-based promoters: the Cp2ZrCl2/AgClO4 method produced the 
disaccharides in 97 % yield in a 7/1 β/α-ratio and the Cp2HfCl2/AgClO4 process afforded 
stereoselectively the β-anomer in 95 % yield (Entries 4 and 5). 
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   Table 1. Glycosylation of disaccharide 252 with BnOH by various promoters. 
 Entry Promoter (eq.) Yield (%)c) β/α  
 1 BF3.OEt2 (1.3)a) - -  
 2 Me3SiOTf (1.3)a) - -  
 3 SnCl2 (1.3), AgClO4 (1.3)a) 16 β  
 4 Cp2ZrCl2 (1.3), AgClO4 (2.6)b) 97 7/1  
 5 Cp2HfCl2 (1.3), AgClO4 (2.6)b) 95 β  
   a) -78 °C → 25 °C, 10 h; b) -78 °C → -20 °C, 30 min; c) based on 252. 
 
Since the hafnocene-promoter resulted in exclusive formation of the desired β-
glycoside of 260, the next experiments examining the effect of various acceptors on the 
glycosylation were performed by using the Cp2HfCl2/AgClO4 activation method (Table 2). 
All the acceptors tested gave high yields and the reactions were complete in 30 min at low 
temperature. Good β-selectivity was observed with cyclohexanol, tert-butanol and benzyl 
alcohol with a methoxycarbonyl group (Entries 1, 2 and 3), whereas the use of phenol led 
to complete α-selectivity (Entry 5). 
 
   Table 2. Glycosylation of disaccharide 252 with various acceptors.a) 
 Entry Acceptor Yield (%) β/αb)  
 
1 
OH
 
91 11/1 
 
 2 OH
 
85 8.4/1  
 
3 
OH
MeO2C  
94 8.7/1 
 
 
4 
OH
MeO2C
AcO
 
95 4.2/1 
 
 
5 
OH
 
87 α 
 
  a) Conditions: 252/ROH/Cp2HfCl2/AgClO4 = 1/1.4/1.3/2.6, 4Å molecular sieves, CH2Cl2, 
-78 °C → -20 °C; b) determined by 1H NMR. 
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The opposite selectivity in the presence of phenol was explained as follows: 'the β-
phenyl glycoside, formed if any, would be more reactive, thereby undergoing a 
neighbouring group-assisted departure of the phenoxide, possibly in a reverse manner, and 
the less reactive α-glycoside was accumulated.'69 
 
3.3.1. Stereochemical aspects 
 
The final issue of the pradimicin synthesis was the examination of the conformer 
dependence of the diol acceptor of the aromatic aglycon. The diequatorial and diaxial 
(S,S)-phenanthrendiols 26179 and the mono-protected derivatives 262 and 263 were chosen 
as the model substrates (Fig. 13). Glycosylation experiments were performed with the 
disaccharide donor 252 employing the Cp2HfCl2/AgClO4-protocol as the promoter. The 
results are presented in Table 3. 
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Figure 13. Structures of the trans-phenanthrendiol derivatives employed in the 
glycosylation study. 
 
Glycosylation with diols 261eq and 261ax proceeded with poor yields, presumably due 
to internal hydrogen bonding that makes the hydroxy group less reactive (Entries 1 and 2). 
In the case of the diaxial 261, only β-glycosylation took place, although the formation of 
bis-glycosylated product was also observed. Both the mono-protected acetates 262 and 
benzyl ethers 263 gave excellent yields, but the stereoselectivity was dependent on the 
protecting group. Glycosylation with the acetates 262 gave modest stereoselectivities, 
whereas better β-selectivities were obtained when using benzyl protected phenanthrendiols 
263 (Entries 3-6). However, in all cases, the diaxial conformers offered higher β-
selectivity than the diequatorial counterparts. 
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            Table 3. Glycosylation of various phenanthrendiol derivatives with 252.a) 
 Entry Diol Yield (%)b) α/β  
 1 261eq 69 1/4.7  
 2 261ax 55 (28)c) β  
 3 262eq 94 1/2.6  
 4 262ax 91 1/4.6  
 5 263eq 94 1/6.7  
 6 263ax 90 1/7.6  
            a) Conditions: 252/acceptor/CpHfCl2/AgClO4 = 1/1.4/1.3/2.6, MS 4Å, CH2Cl2,  
         -78 °C → -20 °C; b) based on 252; c) yield of the bis-glycosylated product. 
 
The latest report by Suzuki and co-workers discussed the modification of the B-ring of 
the pradimicin aglycon in a manner that would allow selective glycosylation of the 
disaccharide moiety at the C5 hydroxyl group.80 Direct glycosylation attempts between the 
disaccharide donor 252 and the aromatic aglycon 235 had resulted in no selectivity, due to 
the trans-configuration of the vicinal C5/C6 hydroxyls of the B-ring. In order to ensure the 
regioselective coupling to the C5 hydroxyl, the C6 hydroxyl group was protected. The 
synthesis strategy for the preparation of the suitable tetracyclic intermediate 268 is shown 
in Scheme 35. 
Compound 264 was first oxidized to the corresponding aldehyde and the MOM-
protection was replaced with a silyl group to produce compound 265. Treatment of 265 
with benzyl trimethylsilyl ether and a catalytic amount of TMSOTf gave acetal 266, which 
after cleavage of the silyl protection was oxidized to the aldehyde-acetal 267. 
Stereoselective reductive pinacol type cyclization of 267 by SmI2 and BF3.OEt2 in THF 
furnished the desired C6-protected tetracycle 268 with perfect trans-selectivity (trans/cis, 
>99/<1). 
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Scheme 35. i) MnO2, CH2Cl2; ii) 6 M HCl, DME (1:2), 40 °C; iii) TBDPCl, imidazole, 
DMF; iv) TMSOBn, TMSOTf; v) n-Bu4NF, THF; vi) SmI2, BF3.OEt2, THF. 
 
In conclusion, the Suzuki group has reached closest towards the total synthesis of 
pradimicin A by accomplishing the synthesis of the aglycon part and performing the 
glycosylation studies for the attachment of the model disaccharide fragment to the 
aromatic skeleton. 
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4. Synthesis of the disaccharide fragment of pradimicin A  
 
4.1. General 
 
The target of my research was the synthesis of the amino sugar unit of the antibiotic 
pradimicin A (Fig. 14), starting from the amino acid L-threonine, and the coupling of the 
sugar fragment synthesized to a suitably protected, commercially available D-xylose 
derivative to build up the disaccharide unit of pradimicin A.  
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Figure 14. Pradimicin A. 
 
Three major factors had to be taken into consideration when planning the synthesis: 
 
1) preparation of the convenient glycosyl acceptor of the disaccharide i.e. the amino 
sugar unit 
2) employment of the proper glycosyl donor 
3) choice of suitable protective groups 
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A glycosidic bond is usually formed by displacement of a leaving group at the anomeric 
position of the glycosyl donor with the free hydroxyl group of the glycosyl acceptor (Fig. 
15). Thus, glycosylation is a substitution reaction where the glycosyl acceptor acts as the 
nucleophile and the glycosyl donor is the electrophile. An important consideration often is 
that the anomeric position of the acceptor is differentially functionalized from the 
anomeric position of the donor in order to retain the glycosyl acceptor unaffected by the 
activation conditions. Another noteworthy factor is that the glycosylation reactions must 
be carried out under completely anhydrous conditions, since the presence of even a small 
amount of water will result in the formation of hydrolysis products. 
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Figure 15. Formation of the glycosidic linkage. LG = leaving group. 
 
When planning the synthesis of the disaccharide unit, the factors mentioned above had 
to be taken into account. In addition, the amino sugar part of the disaccharide had to be 
designed to function both as the acceptor and the donor, in order to facilitate the coupling 
of the disaccharide fragment to the pradimicin aglycon later on.  
1), 2) There exist several commonly used glycosyl donors to choose from, including 
glycosyl bromides and fluorides, thioglycosides, selenoglycosides, sulfoxides, glycals and 
trichloroacetimidates. Glycosyl bromides were the first glycosyl donors used for the 
disaccharide formation by Koenigs and Knorr81 and are still widely employed, but they are 
not particularly stable and are usually generated in situ and employed directly after their 
formation. In comparison, glycosyl fluorides are much more stable and can be easily 
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prepared from the corresponding thioglycosides or directly from the sugars by conversion 
of the free anomeric hydroxyl group to fluoride. Thioglycosides are also very useful 
donors since they are stable and will not react until they are activated under particular 
conditions. Thioglycosides are easily prepared from the corresponding anomeric acetates. 
Since both glycosyl fluorides and thioglycosides are unaffected by the activation 
conditions required for the activation of the other, a partially protected glycosyl fluoride 
can be employed as a glycosyl acceptor with a thioglycoside donor, and vice versa. These 
are termed orthogonal glycosylation protocols. For this reason, a combination of glycosyl 
fluorides and thioglycosides was chosen for the preparation of the disaccharide fragment 
of pradimicin A. 
3) The third crucial part in the synthesis was the choice of proper protecting groups. In 
a multi-step synthetic sequence, the protection has to be stable under a variety of 
subsequent reaction conditions, and it should be readily removed at the end of the 
synthesis route without affecting other functionalities or the glycosidic bond. Furthermore, 
the stereochemical outcome of the glycosylation can also be partly controlled by the type 
of protection, employing either participating or non-participating neighbouring groups at 
the 2-position.  
Neighbouring group participation of an ester protecting group, such as an acetate or a 
benzoate, will result in the formation of 1,2-trans glycosidic linkages.82 Figure 16 
illustrates an example of a substitution reaction of an acetylated sugar having generalized 
anomeric leaving group LG with a nucleophile Nu to produce a glycosidic bond. The first 
step of the reaction mechanism consists of an SN1 type cleavage of the leaving group (LG) 
leading to the formation of the glycosyl cation. In the next stage, the glycosyl cation is 
stabilized by the participation of the carbonyl oxygen of the acetate at the 2-position 
generating the cyclic oxonium ion. Finally, an SN2 type attack of an external nucleophile 
(Nu) produces the glycosidic linkage trans to the 2-hydroxyl group. As shown in Figure 
16, a gluco starting sugar gives access to the β-glucoside whereas a manno derivative 
affords the α-isomer. 
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Figure 16. Neighbouring group participation in the formation of 1,2-trans-glycosides. 
 
Keeping these factors in mind, the synthetic route for the preparation of the amino 
sugars 275, starting from L-threonine, was designed. The synthesis path is described in 
general in section 4.2 and each stage of the reaction course is discussed in detail in the 
latter part of this chapter. 
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4.2. L-Threonine based approach to the synthesis of the amino sugar 
fragment of pradimicin A 
 
The synthesis of the target amino sugars 275 is a multi-step process, starting from the 
commercially available amino acid L-threonine (Scheme 36). The work concerning the 
preparation of some deoxy-4-aminohexoses from L-threonine, accomplished earlier in our 
group,34 offered the basis for the amino acid based synthesis of the deoxysugar derivatives 
275a and 275b. 
To begin with, the amino aldehyde 40 was prepared from L-threonine according to the 
modified procedure developed earlier in our group.34 The t-butoxycarbonyl group (BOC) 
was chosen for the amine protection for two reasons: 1) the behavior of the BOC-group 
under the reaction conditions up to E-enoate 101 was already familiar and would not 
require any adjustments, which would have been the case when introducing a totally new 
protecting group, 2) it is reasonably stable under the acidic reaction conditions required 
during the synthesis sequence. 
Conversion of the aldehyde 40 to the E-enoate 101 was accomplished by a modified 
Horner-Wadsworth-Emmons olefination, employing 18-crown-6 ether to improve the 
dissolution of the base used.34 Ruthenium-catalyzed dihydroxylation of the double bond 
afforded diol 269, which after acetate protection, was subjected to acid-catalyzed 
cyclization to produce lactone 271. Reduction of lactone 271 by platinum-catalyzed 
hydrogenation, followed by fluorination with DAST afforded a mixture of α- and β-
fluorides 273, which were separated by flash chromatography. N-Methylation for both 
anomers, followed by deprotection and selective benzoyl protection at the 2-position 
furnished the target amino sugars 275a and 275b. The 2-position of the monosaccharides 
was protected by a participating benzoyl ester, in order to ensure the correct 
stereochemical outcome of the future glycosylation between the disaccharide fragment to 
be formed and the pradimicin aglycon. 
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Scheme 36. i) AcCl, MeOH, 50 °C; ii) Et3N, (BOC)2O, MeOH/CH2Cl2; iii) DMP, 
BF3.OEt2, CH2Cl2; iv) DIBAL-H, toluene, -78 °C; v) MeO2CCH2P(O)(OMe)2, K2CO3, 18-
c-6, toluene, rt; vi) NaIO4, RuCl3.x(H2O), EtOAC/CH3CN 1:1; vii) Ac2O, DMAP, CH2Cl2; 
viii) gl. acetic acid, 60 °C; ix) PtO2/H2, EtOAc, rt; x) DAST, EtOAc, 0 °C → rt; xi) MeI, 
Ag2O, DMF; xii) 0.1 M NaOMe, MeOH, 0 °C; xiii) BzCl, Bu2SnO, Et3N, reflux. 
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4.3. Formation of E- and Z-enoates via modified Horner-
Wadsworth-Emmons olefination 
 
The Horner-Wadsworth-Emmons olefination reaction can generate both the 
thermodynamic and kinetic olefination products i.e. E- and Z-enoates, respectively (Fig. 
17). The process favors the formation of the thermodynamically more stable E-olefins, but 
the E/Z ratio can be affected by the metal cation, reaction temperature and the solvent 
employed.83 According to the observations by Thompson and Heathcock, the alkyl 
substitution pattern on the aldehyde had the greatest effect on the E/Z ratio: the solvent, 
base or the reaction temperature had significant effects on the E/Z ratio in the reactions 
with mono- and disubstituted aldehydes, but olefination of the trisubstituted aldehyde 
produced the E-enoate exclusively, regardless of the reaction conditions employed. 
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Figure 17. Mechanism for the Horner-Wadsworth-Emmons reaction. 
 
For the olefination of the mono- and disubstituted aldehydes, among the metal cations 
examined were lithium, sodium and potassium. The effect of temperature (rt vs. –78 °C) 
and the solvent (THF vs. DME) was greatest with the use of lithium cation and was 
decreased when employing sodium or potassium as the cation. At room temperature, 
sodium and potassium cations afforded moderated E-selectivities in both solvents, but the 
best E/Z-ratio for both types of aldehydes was obtained by the use of lithium at room 
temperature in DME. 
In the synthesis towards the amino sugar derivatives 275, the formation of the E-isomer 
was desired. The results published earlier in our group had shown that the best E-
selectivity in the modified Horner-Wadsworth-Emmons olefination of the amino aldehyde 
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40 had been achieved by the combined use of trimethyl phosphonoacetate, potassium 
carbonate and 18-crown-6 ether in toluene, affording a 19:1 E/Z-ratio.34 However, in order 
to reduce the overall costs of the synthesis sequence by avoiding the use of a large excess 
(200 mol-%) of the expensive 18-crown-6 ether in this particular step, we examined the 
effect of different bases (especially the metal cation) on the E/Z-selectivity in the absence 
of 18-crown-6. Trimethyl phosphonoacetate was used as the phosphonate carbanion and 
the bases examined were KHMDS, NaH and BuLi. The solvents employed were THF (for 
BuLi and NaH) or toluene (for KHMDS) (Scheme 37). 
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Scheme 37.  
 
In a typical procedure, trimethyl phosphonoacetate and the base were combined and 
stirred with the solvent at ~0 °C for 1 h before addition of the aldehyde 40. After addition 
of the aldehyde at –10 °C, the reaction was brought to rt and stirring was continued either 
for 1.5 h or overnight. The reactions were carried out at rt in order to produce mainly the 
thermodynamic E-olefination product 101. The reaction time was lengthened in some 
experiments for comparison, in order to see whether the prolonged reaction time would 
increase the E/Z-ratio. As can be seen in Table 4, the prolonged reaction time had no effect 
on the stereoselectivity. 
The absence of 18-crown-6 ether resulted in modest stereoselectivities, and the 
difference between KHMDS and NaH as the base was insignificant: the E/Z-ratio of the 
olefination products with KHMDS was 6:1 and with NaH 5:1. Olefination employing 
BuLi as the base afforded a 1:1 mixture of E- and Z-enoates. 
The results observed for KHMDS are comparable to those recorded earlier in our group 
for the olefination of aldehyde 40. The reaction of 40 with trimethyl phosphonoacetate and 
K2CO3 had afforded an E/Z-ratio of 6:1 in toluene and of 4:1 in acetonitrile. The effect of 
Na+ and Li+ cations on the olefination of 40 had not been reported in that study. 
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Table 4. The effect of base in the formation of E- and Z-enoates. 
Entry Base/Solvent Reaction time E/Za) Yield (%) 
1 KHMDS/toluene 1.5 h 6:1 91 
2 KHMDS/toluene overnight 6:1 90 
3 NaH/THF 1.5 h 5:1 95 
4 NaH/THF overnight 5:1 94 
5 BuLi/THF 1.5 h 1:1 85 
6 BuLi/THF overnight 1:1 85 
a) The E/Z-ratio was determined by HPLC. 
 
In conclusion, in order to obtain the E-olefin 101 in high stereoselectivity, the presence 
of 18-crown-6 ether in the reaction system was required. The other alternative was the 
awkward and time-consuming separation of the E/Z-mixture by flash chromatography. 
 
4.4. Ruthenium-catalyzed cis-dihydroxylation of the double bond 
 
Dihydroxylation of the E-enoate 101 was performed by ruthenium-catalyzed 
dihydroxylation, employing NaIO4 as the oxidizing agent and RuCl3.xH2O as the 
catalyst.84 The advantage of the oxidative ruthenium catalysis over the traditional, osmium 
tetroxide catalyzed dihydroxylation method85 was extremely short reaction time. The 
reaction was essentially complete after 3 min vigorous stirring of the enoate 101 with 
NaIO4 and RuCl3.xH2O in a biphasic solvent system of EtOAc/MeCN/H2O at 0 °C. In 
order to avoid overoxidation, the reaction was stopped exactly after 3 minutes. The above 
cis-hydroxylation of 101 produced a 3:1 mixture of the diols 269a and 269b, which were 
purified by flash chromatography in 48 % and 18 % yield, respectively (Scheme 38). 
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Scheme 38. i) NaIO4, cat. RuCl3.xH2O, EtOAc/MeCN/H2O (3:3:1), 0 °C, 3 min. 
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The mechanism of the ruthenium-catalyzed dihydroxylation is not clear, but the cis-
stereochemistry of the resultant diols derived from cycloalkenes suggests a cyclic 
intermediate.86 Two basic mechanisms for the ruthenium- or osmium-catalyzed 
dihydroxylation have been proposed: the classical, concerted [3+2] cycloaddition 
mechanism and a stepwise [2+2] mechanism (Fig. 18). The early DFT (density functional 
theory) studies by Sharpless et al. indicated the intermediacy of the metallaoxetane 
intermediate i.e. the [2+2] mechanism87 but more recent studies have provided strong 
support for the concerted [3+2] mechanism.88 
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Figure 18. Possible pathways for the ruthenium-catalyzed cis-dihydroxylation. 
 
4.5. Lactonization 
 
The original strategy to generate the desired deoxysugar 277 was to expose the diol 269a 
to acid-catalyzed lactonization to form the bicyclic lactone 276, having the two hydroxyl 
groups simultaneously protected. After lactonization, successive N-methylation, 
fluorination and deprotection would have followed (Scheme 39). 
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Scheme 39.  
 
The idea to form the bicyclic lactone 276 arose from the acid-mediated lactonization 
results reported for the L-serine derivative 278 in our group.89 Treatment of the Cbz-
protected, L-serine derived anti-alcohol 278 with camphorsulfonic acid at rt for 12 h had 
produced the bicyclic lactone 279 (Scheme 40). 
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Scheme 40. i) CSA, CH2Cl2, rt. 
 
In the case of the syn-diol 269a, the reaction with CSA resulted in the formation of the 
O,O-acetonide 280 instead of the desired bicyclic lactone (Scheme 41). The major 
difference between the L-serine derived alcohol 278 and the compound 269a is the anti- 
vs. syn-configuration of the starting diol. If simple molecular models built up of both of 
these molecules are compared, one can easily notice that the bicyclic lactone to be 
generated from the syn-derivative 269a would have much more strain than the one formed 
from the anti-alcohol 278. 
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Scheme 41. i) CSA, CH2Cl2, rt. 
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Another attempt for the cyclization of 269a was the application of the lactonization 
method developed for Z-enoate 41 in our group.34 Several experiments to find out the most 
convenient acidic cyclization conditions for the Z-enoate 41 had been carried out, and the 
acids examined included formic acid, acetic acid (both 80 % and glacial), CSA, PTSA and 
the Lewis acid BF3.OEt2. Most of the methods tested had afforded a mixture of the open 
chain product 281 and the lactone 42, but the reaction performed in glacial acetic acid at 
60 °C had produced the lactone 42 as the sole product (Scheme 42). 
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Scheme 42. 
 
With the goal to prepare the lactone 282, diol 269a was subjected to the cyclization 
conditions employing acetic acid as the reagent and the solvent at 60 °C. However, instead 
of lactonization, the reaction produced the acetonide 280 (Scheme 43). Evidently, the free 
hydroxyl groups of the diol interfered with the lactonization process and ought to be 
protected before cyclization. 
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Scheme 43. 
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Acetate protection was chosen for the hydroxyl groups of diol 269a due its stability 
under the acidic conditions required for the lactonization. Another reason was that 
acetylation is a simple and rapid process, leading to acetylated products in quantitative 
yield. Treatment of the syn-diol 269a with a 20-fold excess of acetic anhydride and a 
catalytic amount of DMAP in CH2Cl2 produced the acetylated intermediate 270 after 30 
min stirring at rt. Purification by flash chromatography afforded compound 270 in 99 % 
yield. The protected diol 270 was allowed to stir with glacial acetic acid at 60 °C for 6 
days furnishing the lactone 271 together with unreacted 270. The corrected yield for the 
product 271, based on recovered starting material, was 68 % (Scheme 44). 
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Scheme 44. i) Ac2O, DMAP, CH2Cl2; ii) Acetic acid, 60 °C. 
 
4.6. Model oxidation studies by molecular oxygen 
 
Another possibility to obtain the desired monosaccharide derivative 282 could have been 
via epoxidation of lactone 42, followed by ring-opening (Scheme 45).  
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Scheme 45. 
 
In our group, lactone 42 had been prepared from the Z-enoate 41 under acidic reaction 
conditions and several epoxidation experiments for compound 42 had been performed.90 
Epoxidation attempts with m-chloroperbenzoic acid or t-butylhydroperoxide had resulted 
in no reaction (Scheme 46).  
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Scheme 46. 
 
Oxidation with dioxirane had been very slow and led in decomposition of the labile 
oxidant, thus affording only 30 % yield after several days of oxidation (Scheme 47).  
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Scheme 47. 
 
Finally, epoxidation with t-BuOO-Li+, prepared from t-BuOOH and n-butyl lithium, 
had produced the epoxy lactone 283b almost quantitatively, but the product had 
decomposed at temperatures higher than –20 °C. It was also reported, that the epoxide 
283b had been very labile to both the acidic and basic conditions, resulting in 
decomposition during the work-up process.  
 
O
O
NHBOC
Me
42
O
O
NHBOC
Me
283b
O
i
 
 
Scheme 48. i) t-BuOO-Li+, THF, –20 °C. 
 
As part of the New Oxidation Technologies – Programme, supported by TEKES (the 
National Technology Agency of Finland) and several Finnish companies, epoxidation and 
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allylic oxidation studies employing cyclohexene and α-pinene as model substrates were 
accomplished. These oxidations were carried out by molecular oxygen, using various 
cobalt complexes as catalysts. The research concerning the cobalt-catalyzed allylic air 
oxidation of α-pinene performed earlier in our group offered the basis for these oxidation 
experiments. 91 
One major topic of these cobalt-catalyzed air oxidation studies was to examine the 
effect of the catalyst and an additive on the direction of oxidation i.e. epoxidation vs. 
allylic oxidation. Iqbal et al.92 had reported that the direction of oxidation could be defined 
by a suitable cobalt catalyst. In the presence of molecular oxygen and isobutyraldehyde, 
several cyclic alkenes had been selectively oxidized by cobalt Schiff base complexes 288 
or 289 either to the corresponding epoxides or allylic oxidation products. For example, the 
cobalt complex 288 had selectively catalyzed the oxidation of cyclohexene 284 to 
cyclohexene oxide 285 in 87 % yield, whereas the use of the catalyst 289 had produced 2-
cyclohexen-1-ol 286 and 2-cyclohexen-1-one 287 as the major products in 70 % of total 
yield (Scheme 49).  
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Scheme 49. i) O2, 288, IBAL, MeCN, rt, ii) O2, 289, IBAL, MeCN, rt. 
 
Iqbal’s report did not specify more precisely what factors of the cobalt catalysts defined 
the direction of oxidation. Our own hypothesis was that the octahedral vs. tetrahedral 
structure of the complex directed the oxidation i.e. the octahedral catalyst 288 led to 
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epoxidation whereas the tetrahedral complex 289 afforded allylic oxidation products. To 
find out whether this hypothesis was correct or not, we decided to prepare certain cobalt 
complexes of our own and to test them in the air oxidation experiments of our model 
compounds.  
To start with, the literature reaction oxidizing cyclohexene in the presence of IBAL 
with the catalyst 288 was repeated, with expectations to produce cyclohexene oxide 285 
selectively (Scheme 50). Cyclohexene and IBAL (molar ratio 1:2) were dissolved in 
acetonitrile in a round-bottomed flask equipped with an oxygen balloon. The cobalt Schiff 
base complex 288 (5 mol-%) was added to the solution and the reaction mixture was 
stirred at rt for 40 hours. According to the GC analysis, cyclohexene oxide 285 and 2-
cyclohexen-1-one 287 were obtained as the major products in a ratio of 2.5:1, respectively, 
along with formation of 2-cyclohexen-1-ol 286 as the minor product.  
When the tetrahedral Co(py)2Br2-complex93 290 (5 mol-%) was applied to the similar 
oxidation of cyclohexene, the corresponding epoxide and ketone were produced as the 
major products in a ratio of 2:1 as well (Scheme 50). Interestingly, when only 0.13 mol-% 
of Co(py)2Br2-catalyst 290 was employed instead of 5 mol-%, the rate of the oxidation was 
accelerated and the proportion of the epoxide increased; the ratio of cyclohexene oxide 285 
to 2-cyclohexen-1-one 287 was 4:1.  
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Scheme 50. i) O2, IBAL, MeCN, 288 or 290, ii) O2, 288 or 290. 
 
Moreover, in the absence of IBAL, both the cobalt catalysts resulted in allylic oxidation 
of cyclohexene, affording only 2-cyclohexen-1-one 287 and 2-cyclohexen-1-ol 286 
(Scheme 50).  
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Similar results were observed in the cobalt-catalyzed oxidation of α-pinene by 
molecular oxygen. In the absence of any solvent or additive, Co(py)2Br2-catalyst gave 
mainly allylic oxidation products whereas in the presence of IBAL and Co(py)2Br2, α-
pinene was selectively oxidized to α-pinene oxide with no signs of allylic oxidation 
(Scheme 51).  
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Scheme 51. i) O2, IBAL, MeCN, 290, ii) O2, 290. 
 
A question had also been raised whether it was necessary to employ a ready-made 
cobalt complex in the oxidations or whether the complex could be formed during the 
process provided that the reagents needed for the catalyst formation were available. 
Experiments for α-pinene in the absence of IBAL were performed employing either 
Co(py)2Br2 290 as the catalyst or by adding CoBr2.6H2O and pyridine separately into α-
pinene in order to generate the cobalt-pyridine -complex in situ. The reactions were carried 
out at 70 °C by bubbling oxygen through a gas inlet in the bottom of a glass reactor. There 
were no differences between these experiments; in both the cases oxidation proceeded 
normally and allylic oxidation products were obtained as usual.94 A test reaction with the 
plain CoBr2.6H2O as the catalyst was also carried out, but no reaction occurred after one 
day of oxidation. According to these results, the geometry of the cobalt complex did not 
have much effect on the oxidation of α-pinene, but the presence of pyridine was essential 
for the oxidation to take place. 
The influence of pyridine on the oxidation of α-pinene in the presence of IBAL was 
also examined. When the Co(py)2Br2-complex 290 was replaced by plain CoBr2.6H2O, the 
reaction proceeded smoothly as usual, yielding α-pinene oxide 292 as the sole product 
(Scheme 52). In the next experiment, oxidation of α-pinene in the presence of IBAL but 
without a catalyst was performed to find out whether any metal catalyst at all was required 
for the oxidation to take place. Indeed, epoxidation of α-pinene 291 to α-pinene oxide 292 
was completed in 6 hours at rt (Scheme 52). 
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Scheme 52. i) O2, IBAL, MeCN, (290 or CoBr2.6H2O), rt. 
 
Oxidation of cyclohexene in the presence of IBAL without any cobalt catalyst led to the 
formation of cyclohexene oxide as the major product, although the reaction rate was 
slightly slower compared to the experiments with the cobalt catalyst. Different from the 
oxidation of α-pinene, in the case of cyclohexene allylic oxidation took also place and the 
reaction rate was slower.  
In conclusion, these experiments showed that the presence of IBAL in the oxidation of 
cyclohexene and α-pinene resulted mainly in epoxidation, whereas in the absence of the 
aldehyde, allylic oxidation products were obtained. 
 
4.6.1. Cobalt salen and pyrrolidine complexes in the oxidation of cyclohexene 
 
We had proposed that the octahedral structure of the cobalt Schiff base complex 288 
had directed the oxidation of olefins to form epoxides. However, the experiments carried 
out for cyclohexene and α-pinene showed that in the absence of IBAL, the use of complex 
288 resulted in allylic oxidation. Those results led to the assumption that the octahedral 
structure of the catalyst had changed in the substrate during the oxidation process and 
therefore the allylic oxidation had occurred. The effect of the positive and negative charge 
in the cobalt complex 288 on the oxidation process was also worthy of consideration. 
Since the tetrahedral Co(py)2Br2-catalyst was a neutral complex, it was of interest to 
prepare neutral, octahedral cobalt complexes in order to be able to compare the influences 
of the tetrahedral and octahedral structures of the catalysts on the oxidation. Cobalt salen 
complex 295, one of a type of catalysts that are widely used in the epoxidation of olefins, 
was prepared according to the literature procedure from diamine and salicylaldehyde.95  
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Figure 19. Cobalt(II) salen complex. 
 
In addition, a new cobalt pyridine complex 299 was synthesized (Scheme 53). 1,3-
Bis(bromomethyl)-pyridine 297 was prepared in a moderate yield (25 %) according to the 
literature procedure96 by bromination of 2,6-lutidine 296 with an excess of N-
bromosuccinimide in benzene under illumination. One equivalent of compound 297 and 
five equivalents of pyrrolidine in benzene reacted through nucleophilic substitution to form 
1,3-bis[(pyrrolidinyl-N-)methyl]-pyridine 298 in a 74 % yield after Kugelrohr distillation. 
Compound 298 and cobalt(II) nitrate hexahydrate were stirred in absolute ethanol at rt 
overnight to form a purple powder. The crude product was further purified by 
crystallization from absolute ethanol to afford 1,3-bis[(pyrrolidinyl-N-)methyl]-pyridine 
cobalt complex 299 as large, purple crystals in a 69 % yield. 
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Scheme 53. i) NBS, AIBN, hν, benzene, ii) pyrrolidine, benzene, iii) Co(NO3)2.6H2O, 
EtOH. 
 
In order to see if epoxidation would take place, the cobalt catalysts 295 and 299 were 
employed in the air oxidation of cyclohexene in the absence of IBAL. The reactions 
proceeded as usual in the absence of the aldehyde, affording only allylic oxidation 
products of cyclohexene i.e. 2-cyclohexen-1-ol 286 and 2-cyclohexen-1-one 287.  
It was later determined on the basis of X-ray analysis97 that the structure of complex 
299 was rather a trigonal bipyramide than octahedral as it had been considered earlier (Fig. 
20). However, the experiments performed with the neutral, octahedral cobalt salen 
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complex 295 indicated that epoxidation could not be directed only by the octahedral 
structure of the catalyst.  
 
 
 
Figure 20. ORTEP plot of the molecular structure of complex 299. 
 
Based on the above results obtained for cyclohexene and α-pinene it was concluded that 
the structure of the cobalt catalyst did not seem to have a significant role in defining the 
direction of oxidation, but the presence or absence of the aldehyde clearly determined 
whether epoxidation or allylic oxidation occurred.  
The cobalt-catalyzed oxidation was not applied for the epoxidation of the lactone 42 
since the double bond of 42 is electron poor and therefore not easily oxidized. 
 
4.7. N-Methylation attempts 
 
N-Methylation of the lactone 271 was intended to be the next step of the synthesis. The 
commonly used N-methylating agents are methyl iodide and NaH in an appropriate solvent 
such as THF or DMF. Application of these methylating conditions for the lactone 271 
resulted in replacement of the acetate protection at the 2-position by a methoxy group, and 
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removal of the hydrogen at C-2, leading to elimination of the C-3-acetate of the lactone 
ring (Scheme 54). 
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Scheme 54. i) MeI, NaH, THF, rt. 
 
Indeed, removal of the acetate protection can be accomplished under basic reaction 
conditions,98 but the cleavage of the hydrogen atom at the 2-position, followed by the 
double bond formation was not expected. Apparently, the hydrogen atom next to the 
carbonyl group is slightly more acidic than the hydrogen bonded to the nitrogen. 
To avoid deacetylation, examples of N-methylation procedures under neutral reaction 
conditions were sought for in the literature. Kaifu and co-workers had reported of a useful 
N-methylation method for the acetylated sugar derivative 301, by treating compound 301 
with an excess of MeI and Ag2O in DMF (Scheme 55).99 
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Scheme 55. i) MeI, Ag2O, DMF, rt. 
 
This same protocol was applied for the N-methylation of lactone 271. A mixture of 
lactone 271, a 100-fold excess of MeI and 300 mol-% of Ag2O in DMF was protected 
from light and stirred under argon at rt overnight. N-Methylation along with the unwanted 
formation of the double bond took place, producing compounds 303 and 304 in 21 % and 
56 % yields, respectively (Scheme 56). The interesting point of this reaction was the 
partial replacement of the acetate protection at the 2-position by a methoxy group, since 
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the acetates were expected to remain intact under the neutral reaction conditions. It is also 
noteworthy, that the major product was the one having the acetate ester replaced with a 
methoxy group, whereas in the literature under similar reaction conditions the acetates 
were not influenced. 
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Scheme 56. i) MeI, Ag2O, DMF, rt. 
 
Thus, the major problem of this pathway was no longer the cleavage of the acetates, but 
the lactone functionality, making the α-hydrogen highly acidic thus leading to facile 
elimination. It became evident that the introduction of the methyl functionality to the 
amine at the lactone stage through this reaction path was not feasible, and a change in the 
synthetic strategy was required. 
 
4.8. Platinum-catalyzed hydrogenation of the lactone 
 
Since the lactone functionality in the molecule had been the main reason for the 
unsuccessful N-methylation attempts, the order of steps in the synthesis was rearranged. 
Thus, instead of introducing the methyl moiety to the molecule at the problematic lactone 
stage, the plan was to convert the lactone 271 first into the corresponding glycosyl 
fluoride, and to bring the methyl group into the molecule at the fluoride stage. The 
preparation of the fluoride derivative would proceed via hydrogenation of the lactone 271, 
followed by direct fluorination of the anomeric hydroxyl group. 
The results observed in the hydrogenation experiments accomplished for the 
pentenolide derivative 305 in our group100 suggested the use of metal-catalyzed 
hydrogenation of lactone 271 instead of DIBAL-H -reduction. In addition to 
hydrogenation of the double bond of pentenolide 305, platinum-catalysis had also led to 
simultaneous reduction of the carbonyl moiety of the molecule (Scheme 57). The 
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hydrogenation had been carried out under mild reaction conditions at rt and 1 atm pressure, 
employing a balloon filled with H2 as the hydrogen source and PtO2 as the catalyst. 
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Scheme 57. 
 
The above hydrogenation method was applied for the reduction of lactone 271 to 
lactols. The process started with the reduction of platinum(II) oxide to platinum(0) by 
stirring the catalyst in EtOAc under hydrogen atmosphere at rt for 15 min. A solution of 
lactone 271 in EtOAc was added next, and the mixture was stirred under hydrogen at rt for 
6 hours. Finally, the reaction mixture was filtered through a pad of Celite and the solvent 
removed under reduced pressure. Purification of the crude mixture by flash 
chromatography produced a 1:1 mixture of α- and β-lactols 272 in 76 % yield. The 
anomers could be separated from each other by crystallization form EtOAc/hexanes 
(Scheme 58). 
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Scheme 58. 
 
By this simple and efficient procedure, the carbonyl group of the lactone ring was 
successfully reduced to a free lactol, maintaining the acetate protection intact. 
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4.9. Preparation of the glycosyl fluoride by direct fluorination 
 
Glycosyl fluorides can be prepared easily under mild reaction conditions by indirect or 
direct methods. The indirect methods include the fluorination of the corresponding 
thioglycoside by a combination of DAST and NBS or HF.pyr complex and NBS.101 
Examples of the direct fluorination procedures, in which the free anomeric hydroxyl group 
is replaced by fluorine, are the use of DAST,102 2-fluoropyridinium salts,103 hydrogen 
fluoride-pyridine104 and hexafluoropropene-amine complex.105 For the preparation of the 
corresponding glycosyl fluorides from the lactols 272 I chose the high-yielding, widely 
used DAST-method, since the reaction proceeds under mild and neutral conditions. The 
drawback of this procedure is the formation of α/β-anomeric mixtures of fluorides. The 
general mechanism for the direct fluorination of the anomeric hydroxyl group by DAST is 
presented in Figure 21. 
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Figure 21. General mechanism for the DAST-fluorination. 
 
In a typical experiment, 150 mol-% of DAST was added to a stirred solution of lactols 
272 in THF at 0 °C. After removal of the cooling bath the reaction was stirred at rt for 30 
min until TLC indicated the completion of the reaction. After standard aqueous work-up 
the crude mixture of fluorides was separated by flash chromatography. The ratio of the α- 
and β-anomers formed was to some degree dependent on the solvent employed. In order to 
affect the α/β-ratio, some solvent experiments were carried out. The conversion of lactols 
272 to the corresponding glycosyl fluorides 273a and 273b by DAST is shown in Scheme 
59. 
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Scheme 59. i) DAST, THF, 0 °C → rt, 30 min. 
 
Posner and Haines have studied the effect of various solvents on the anomeric ratio of 
the direct fluorination of 2,3,5-tri-O-benzyl-D-ribofuranose 308 (Scheme 60).102b All the 
solvents examined produced the β-fluoride 309 as the major product. The best β/α-ratio 
was achieved by using a polar solvent such as THF whereas CH2Cl2 gave the poorest 
selectivity (Table 5). 
 
O
OH
OBnBnO
BnO
O
F
OBnBnO
BnO
DAST
Solvent
308 309  
Scheme 60. 
 
   Table 5. Solvent effect on the fluorination of 308 by DAST. 
 Entry Solvent β:α  
 1 CH2Cl2 2.0 : 1.0  
 2 Toluene 3.7 : 1.0  
 3 CCl4 4.1 : 1.0  
 4 Et2O 4.2 : 1.0  
 5 DMTHF 5.7 : 1.0  
 6 THF 9.9 : 1.0  
 
In the case of lactols 272, the DAST-fluorination in THF afforded a 1:3 mixture of α- 
and β-anomers, respectively. The result correlated with the observations of Posner and 
Haines, although the selectivity was modest. In order to achieve better selectivities, the 
effect of a variety of solvents such as CH2Cl2, toluene, EtOAc, DME and 1,4-dioxane on 
the α/β-ratio was examined. 
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The expectation was that polar solvents similar to THF, such as 1,4-dioxane and DME 
would produce mainly the β-fluoride 273b whereas the use of less polar solvents such as 
CH2Cl2 or toluene would increase the formation of the α-anomer 273a. One limitation for 
these experiments was the insolubility of the highly polar lactols 272 in aprotic solvents; 
they barely dissolved in toluene. The results of the solvent experiments are listed in Table 
6. 
As expected, employment of less polar solvents such as toluene or CH2Cl2 in the direct 
fluorination of lactols 272 by DAST resulted in increase of the α/β-ratio from 1:3 to ~1:1 
(Entries 1 and 4). Instead, the increase in the solvent polarity did not improve the β-
selectivity as was expected. On the contrary, fluorination carried out in DME and 1,4-
dioxane afforded a mixture of α- and β-fluorides in a ratio of 1.1:1 and 1:1.4, respectively 
(Entries 2 and 5). In conclusion, all the solvents studied except THF gave basically 1:1 
mixture of α- and β-anomers.  
 
   Table 6. Solvent effect on the α-/β-ratio of the direct fluorination of 272 by DAST. 
 Entry Solvent Yield (%) α:β  
 1 
 
75 1.0 : 1.0  
 2 O O  80 1.1 : 1.0  
 3 
O
O  
80 1.0 : 1.2  
 4 CH2Cl2 77 1.0 : 1.3  
 
5 
O
O
 
63 1.0 : 1.4 
 
 6 
O  
85 1.0 : 3.0  
          The α:β ratio was determined by 1H NMR. 
 
Since the two anomers were easily separated by flash chromatography, no more effort 
was put to study the α/β-selectivity of the fluorination. Keeping the future glycosylation of 
the pradimicin disaccharide fragment to the aromatic aglycon part in mind, it would not 
matter if the glycosyl donor would be the anomeric mixture of fluorides. As presented in 
Figure 16 on page 70, the participating neighbouring group at the 2-C-position of the 
glycosyl donor would favor the formation of the 1,2-trans-glycosidic linkage as required. 
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However, for clarity and to help the analyses of the following reaction steps, the two 
fluorides were separated at this stage. Both anomers were subjected to similar 
transformations in order to prepare both the α- and β-glycosyl fluorides 275a and 275b. 
After purification of the fluorides 273a and 273b, I succeeded in crystallizing the β-
anomer 273b from chloroform. The crystal structure analysis was carried out and the 
configuration of the β-fluoride 273b was confirmed (Fig. 22).97 
 
 
 
Figure 22. The crystal structure of β-fluoride 273b. 
 
4.10. N-Methylation of fluorides 
 
N-Methylation attempts for the lactone 271 were discussed in Section 4.7. It was observed 
that the process had resulted in the formation of a double bond as well as replacement of 
the acetate ester by a methoxy group along the desired N-methylation. In order to avoid 
these problems arising from the highly acidic hydrogen atom next to the carbonyl moiety 
of the lactone ring, the lactone 271 was converted to the corresponding fluorides 273a and 
273b. Both the α- and β-fluorides were N-methylated. 
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4.10.1. Attempted N-methylation by methyl iodide and sodium hydride 
 
N-methylation of fluoride 273 was first attempted by the MeI/NaH-method, but no 
reaction occurred when 95 mol-% of NaH and 250 mol-% of MeI was used. When a large 
excess of both NaH (320 mol-%) and MeI (30-fold excess) were employed, the acetate 
protective groups were replaced by methoxy groups instead of N-methylation (Scheme 
61). Removal of the acetate protection in the presence of NaH had been already noticed in 
the case of lactone 271 and therefore, no further effort was put on the MeI/NaH-method.  
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Scheme 61. i) MeI, NaH, THF, rt. 
 
4.10.2. N-Methylation by methyl iodide and silver oxide 
 
Both the α- and β-fluorides 273a and 273b were subjected to the N-methylation 
conditions using MeI in the presence of Ag2O. According to the method of Kaifu et al.,99 a 
200-fold excess of MeI and 300 mol-% of Ag2O were employed in the methylation process 
of 273b performed in distilled DMF. The reaction mixture was protected from light and 
stirred at rt for 4 h. Filtration through a pad of Celite, followed by aqueous work-up 
afforded the desired N-methylated product 274b along with the side products 311b and 
312b. The crude product mixture was purified by flash chromatography to afford the N-
methylated β-fluoride 274b in 46 % yield (Scheme 62).  
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Scheme 62. i) MeI, Ag2O, DMF, rt, dark. 
 
N-Methylation of the α-fluoride 273a was accomplished similarly, yielding the desired 
N-methylated product 274a, in which both acetates had remained intact, along with the 
side products 311a and 312a, in which one of the acetates had been replaced by a methoxy 
functionality. The side products were not separated from each other. The yield for the α-
fluoride 274a was 42 % (Scheme 63). 
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Scheme 63. i) MeI, Ag2O, DMF, rt, dark. 
 
To sum up, in the case of fluorides the formation of the double bond was avoided, but 
the problem concerning the partial replacement of the acetate esters by a methoxy group 
remained. In a typical experiment, the reaction was allowed to proceed for 2-3 hours after 
which the amount of side products started to exceed the amount of the desired product, and 
the reaction was stopped despite the unreacted starting material left. If the reaction was 
allowed to proceed until all the starting material had been consumed, the product mixture 
consisted mainly of the side products.  
To reduce the formation of the side products, the effect of the amount of MeI in the 
reaction system was examined. Thus, the amount of MeI was cut to one tenth of the 
original amount, but the reaction proceeded in a similar way as described above, although 
a bit slower. The quality of the reagents had an effect only on the reaction rate as well, not 
the product distribution. If a newly opened bottle of MeI was used or freshly prepared 
Ag2O employed in the process, the reaction proceeded faster but resulted in the same 
product distribution as reported. 
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It was reasoned that the possible explanation for the formation of the side products was 
the presence of moisture in the reaction system, although the reactions were performed in 
distilled DMF under argon atmosphere. 
 
4.10.3. Attempted N-methylation by MeOTf and 2,6-di-tert-butyl-4-
methylpyridine 
 
N-Methylation for fluorides 273 was also attempted by using methyl triflate as the 
methylating agent in the presence of 2,6-di-tert-butyl-4-methylpyridine as the base 
(Scheme 64). It was assumed that methylation would proceed via an SN2-mechanism and, 
therefore, nitrogen as a soft nucleophile would favor the attack of MeOTf as a soft 
electrophile over MeI as a harder electrophile. However, after stirring the reaction at rt 
overnight, the starting material was recovered unchanged.  
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Scheme 64. i) MeOTf, 2,6-di-tert-butyl-4-methylpyridine, CH2Cl2, rt, overnight. 
 
Lactone 271 was also subjected to above N-methylation conditions but with no success 
(Scheme 65). 
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Scheme 65. i) MeOTf, 2,6-di-tert-butyl-4-methylpyridine, CH2Cl2, rt, overnight. 
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4.11. Indirect methods for the preparation of the glycosyl fluoride 
 
Glycosyl fluorides can be also prepared by indirect methods via formation of 
thioglycosides. In the N-methylation process of fluorides 273, formation of the side 
products could not be avoided and the separation of the N-methylated product from the 
side products by flash chromatography had been troublesome. Therefore, it was of interest 
to examine also the indirect route for the preparation of the desired glycosyl fluorides and 
to find out, whether the thioglycoside counterparts would be easier to separate from the 
side products possibly formed. The aim was to acetylate the anomeric mixture of lactols 
272 by standard conditions and then subject it to either N-methylation or thioglycosylation 
conditions to produce the N-methylated thioglycoside derivatives 315, the precursors of 
the target glycosyl fluorides 274 (Scheme 66). 
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Scheme 66.  
 
Acetylation of the anomeric position of lactols 272 by acetic anhydride and DMAP was 
accomplished in 30 min, producing a mixture of acetylated α- and β-anomers 314 almost 
in quantitative yield (Scheme 67). N-Methylation of the acetylated intermediate 314 was 
attempted by the MeI/Ag2O-method by stirring the reaction mixture at 50 °C overnight, 
but most probably, a mixture of N-methylated product 316 and the starting material 314 
was obtained. The spots of the product and the starting material were hardly separated 
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from each other on the TLC-place and therefore, it was difficult to determine whether the 
reaction had been completed or not. 
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Scheme 67. i) Ac2O, DMAP, CH2Cl2, rt, 30 min, ii) MeI, Ag2O, DMF, 50 °C. 
 
Since the N-methylation of 314 resulted basicly in inseparable mixture of the product 
and the starting material and moreover, included a mixture of α- and β-anomers, I decided 
to convert the acetyl intermediate 314 first to its corresponding thioglycoside derivative 
317 to find out whether the thioglycoside anomers could be separated from each other. 
Compound 314 was allowed to stir with an excess of thiophenol and BF3.OEt2 at rt 
overnight, but according to TLC-analysis, mostly baseline material had been formed, 
probably due to the cleavage of the BOC-protection under the acidic reaction media 
(Scheme 68). Thus, the indirect route for the preparation of glycosyl fluorides 274 was 
abandoned.  
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Scheme 68. i) SPh, BF3.OEt2, rt, overnight. 
 
4.12. Deacetylation 
 
The last steps in the preparation of the monosaccharide derivatives 275a and 275b were 
the cleavage of the acetate protection and the regioselective benzoyl protection at the 2-
position of the sugar ring. A convenient way for the deacetylation is the use of basic 
alcoholic solution at 0 °C,98 but it was also reported recently, that the absolute methanol 
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dried over 3Å molecular sieves removes the O-acetyl group due to the existence of 
methoxy species generated by the 3Å sieves.106 
Deacetylation for fluoride 274b was accomplished in basic methanol solution, using 
either NaOMe or K2CO3 as the base (Scheme 69). In both methods, to a cooled (0 °C) 
solution of fluoride 274 in MeOH was added either 0.1 M solution of NaOMe in MeOH or 
a catalytic amount of K2CO3. The reaction was stirred under argon at rt for 4 hours until 
the starting material had been mostly consumed. If the reaction time was prolonged, 
decomposition products near the baseline appeared. The reaction was neutralized by 
filtration of the cold reaction mixture through a short pad of silica, followed by successive 
washes by cold MeOH. Concentration gave the crude product, which was purified by 
gradient flash chromatography to furnish the deacetylated amino sugar 318b as a white 
solid. The yields for the β-fluoride 318b by NaOMe- and K2CO3-methods were 74 % and 
70 %, respectively. 
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Scheme 69. i) 0.1 M NaOMe/MeOH, MeOH, rt, 4 h, 74 %, ii) K2CO3 (cat.), MeOH, rt,     
4 h, 70 %. 
 
Deprotection for the α-anomer 274a was performed in a similar way, employing 0.1 M 
solution of NaOMe in MeOH (Scheme 70). The deacetylated α-fluoride 318a was 
produced in 71 % yield. 
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Scheme 70. i) 0.1 M NaOMe/MeOH, MeOH, rt, 4 h, 71 %. 
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4.13. Regioselective benzoyl protection 
 
4.13.1. Attempts for the regioselective benzoylation by BzCl and pyridine 
 
In the synthesis of the amino sugar derivative 251 of pradimicin A, Kato et al. had 
selectively introduced the benzoyl group to the 2-position of the sugar using BzCl and 
pyridine.69 Benzoylation of α-fluoride 259 had afforded ca. 8:1 mixture of 2-O- and 3-O-
mono-benzoates 251 and 319, giving the desired 2-O-benzoyl derivative in 50 % yield 
after recrystallization from EtOAc (Scheme 71). 
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Scheme 71. i) BzCl, pyridine, 0 °C → rt, 15 h, 50 %. 
 
When the β-fluoride 318b was subjected to similar benzoylation conditions employing 
105 mol-% of BzCl and pyridine as the solvent, most of the starting material remained 
unreacted after stirring at rt overnight. When a catalytic amount of DMAP was added in 
order to accelerate the reaction rate, formation of mono-benzoates was observed but most 
of the starting material remained still unaffected. If the amount of BzCl was increased 
from 105 mol-% to 150 mol-%, mainly the disubstituted fluoride 321 was produced along 
the monosubstitution products 275b and 320 (Scheme 72). Since in the case of the amino 
sugar 318b the regioselective mono-benzoylation could not be obtained by the use of BzCl 
and pyridine, other methods had to be considered. 
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Scheme 72. i) BzCl, pyr, DMAP, CH2Cl2, rt, overnight. 
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An interesting observation of these benzoylation experiments was that the BOC-group, 
usually positioned around the ppm-area of 1.40-1.48 in 1H NMR, was transferred to 1.16 
ppm in the case of the dibenzoylated product 321! Also in the case of 3-O-benzoylated 
product 320 a similar transformation had been observed: the singlet of the BOC-group 
(9H) was split into two singlets (each ~4.5H), situated at 1.24 and 1.13 ppm. In the case of 
2-O-benzoylated compound 275b in which the benzoyl protection and the BOC-group are 
positioned further away from each other, the singlet of the BOC-functionality had 
remained in its usual position at 1.45 ppm. These observations indicate that the relatively 
large benzoyl protection at the 3-position, next to the bulky BOC-protection, causes major 
steric hindrance and thus forces the BOC-group to 'twist' from its initial position, to make 
room for the benzoyl-group.  
 
4.13.2. Regioselective benzoylation via stannylene derivatives  
 
Regioselective benzoylation of hydroxyl groups can be achieved via stannylene 
derivatives, formed by the reaction of the commercially available, polymeric dibutyltin 
oxide (Bu2SnO) in an appropriate solvent.107 The process involves the conversion of the 
dihydroxy derivatives into cyclic stannylenes along with the formation of water as a by-
product, which is usually removed azeotropically from the reaction mixture by a Dean-
Stark trap. The stannylenes undergo regioselective acylation upon treatment with acid 
chlorides, providing products of monosubstitution (Fig. 23). 
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Figure 23. Regioselective acetylation via stannylenes. 
 
The monosubstitution is explained by the constitution of the stannylenes, which are 
generally considered to be dimers having in each subunit one dicoordinated and one 
tricoordinated oxygen.108 An example of such a dimeric structure is shown in Figure 24. 
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The two oxygen atoms of the parent diol are differentiated in the stannylene, one at the 
equatorial (tricoordinated), and the other one at the apical (dicoordinated), position in a 
trigonal bipyramid centered on the tin atom. The regioselective acylation is thought to 
occur at the more nucleophilic, sterically less hindered apical oxygen rather than the 
electronically less enriched equatorial oxygen atom which is relatively protected by the 
threefold coordination. The question of which hydroxyl group of the diol will adopt the 
apical position in the stannylene derivative and hence undergo acylation cannot be 
predicted yet, although the factors affecting on the regioselective outcome of the acylation 
process have been studied.107, 109 
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Figure 24. A dimeric structure for a stannylene intermediate. 
 
The regioselective benzoylation procedure via stannylene intermediates was 
successfully adopted for the fluorides 318a and 318b. The β-fluoride 318b was heated at 
reflux in a round-bottomed flask with 120 mol-% of Bu2SnO, 1000 mol-% of Et3N and 4Å 
molecular sieves in benzene for 2 hours. The molecular sieves were employed for the 
removal of water instead of the Dean-Stark trap due to the small reaction scale. Before 
addition of BzCl to the mixture, the reaction vessel was lifted up from the oil bath and the 
mixture was allowed to cool to rt. After addition of BzCl, the reaction vessel was set back 
into the bath and the mixture was stirred under reflux for about 20 min until all the fluoride 
318b had reacted. Filtration and concentration gave the crude product mixture, which was 
purified by flash chromatography providing the monobenzoylated compounds 275b and 
320 in 70 % and 25 % yields, respectively (Scheme 73). 
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Scheme 73. i) Bu2SnO, Et3N, benzene, 4Å molecular sieves, reflux, then BzCl. 
 
The position of the benzoyl protection in the monosubstituted products 275b and 320 
was deduced by the BOC-shift of the 3-O-benzoylated product 320 in 1H NMR, but the 
final confirmation of the structures was obtained by X-ray analysis.97 The crystal structures 
of the monosaccharides 275b and 320 are shown in Figures 25 and 26. 
 
 
Figure 25. An ORTEP plot of molecular structure of 2-O-benzoylated β-fluoride 275b. 
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Figure 26. An ORTEP plot of molecular structure of 3-O-benzoylated β-fluoride 320. 
 
Regioselective benzoyl protection at the 2-position of the α-fluoride 318a was carried 
out in a similar way as described for the β-anomer 318b (Scheme 74). After refluxing the 
amino sugar 318a with Bu2SnO, Et3N and 4Å molecular sieves in benzene for 2 h, the 
mixture was cooled down to rt and BzCl was added. Refluxing the reaction mixture for 10 
min produced the 2-O-benzoylated fluoride 275a in 46 % yield (corrected yield 75%; 
based on recovered starting material) after flash chromatography. If the reaction time after 
the addition of BzCl was prolonged, also the other regioisomer started to appear according 
to TLC. It was not possible to obtain the crystal structure of the benzoylation product 
275a, thus the position of the benzoyl group was determined on the basis of 1H NMR 
analysis. Since no BOC-shift was observed in the 1H NMR spectrum of compound 275a, 
as would have expected in the case of the 3-O-benzoylated isomer, it was concluded that 
2-O-benzoylated α-anomer 275a had been formed in the process. Benzoylation of the 
hydroxyl group at the 2-position was also proved by the downfield shift of the 
corresponding ring proton from 3.9 ppm to 5.3 ppm. 
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Scheme 74. i) Bu2SnO, Et3N, benzene, 4Å molecular sieves, reflux, then BzCl. 
 
4.14. Concluding steps 
 
The final steps of the disaccharide synthesis were the preparation of the D-xylose derived 
glycosyl donor 250 (Scheme 75) and its coupling with the amino sugar moiety 275 
(Scheme 76). Since the glycosyl fluoride acceptors, such as the amino sugar derivative 
275, are not affected by the activation conditions required for the thioglycoside donors, we 
decided to convert the D-xylose 322 into a thioglycoside donor 250.  
The preparation of thioglycosides is conveniently performed via the corresponding 
acetates. To direct the required β-stereochemistry of the thioglycoside 250 to be formed, it 
was of interest to attach a participating ester functionality, like an acetate ester, at the 2-
hydroxyl position of D-xylose ring. Thus, acetylation of D-xylose was accomplished by a 
convenient procedure, leading to the formation of the tetra-acetylated sugar derivative 323 
in quantitative yield. Preparation of the corresponding thioglycoside by employment of 
thiophenol in acidic media110 produced a mixture of α- and β-glycoside, of which the β-
anomer 250 was isolated in 63 % yield after flash chromatography (Scheme 75). 
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Scheme 75. i) Ac2O, Et3N, DMAP, CH2Cl2, rt; ii) SHPh, BF3.OEt2, CH2Cl2, 0 °C → rt, 
purification by flash chromatography. 
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4.14.1. Activation of the thioglycoside 
 
The final step of the synthesis was the formation of the disaccharide fragment of 
pradimicin A. A number of activators of thioglycosides are known, including bromine,111 
iodine,112 N-bromosuccinimide (NBS),113 NBS/TMSOTf,114 N-iodosuccinimide-triflic acid 
(NIS/TfOH),71 methyl triflate (MeOTf),115 trimethylsilyl triflate (TMSOTf),116 iodonium 
dicollidine perchlorate (IDCP),117 dimethyl(methylthio)sulfonium triflate (DMTST),118 
DMTST/Bu4NBr119 and dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSB).120 
The activators for thioglycosides can be regarded as sources of soft electrophiles, which 
convert the anomeric sulfur to a leaving group.  
The aim in the synthesis of the disaccharide fragment of pradimicin A was to produce 
the 1,2-trans linked β-glycoside 324 (Scheme 76). The activation method involving NIS 
and a catalytic amount of TfOH is perhaps the most widely used procedure for the 
activation of thioglycosides, including phenylthio and ethylthio derivatives. Thus, the 
thioglycosyl donor 250 and the amino sugar acceptor 275b were subjected to the activation 
conditions promoted by NIS and TfOH (Scheme 77). 
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Scheme 76. 
 
The donor 250 and the acceptor 275b were combined and stirred in CH2Cl2 with 4Å 
molecular sieves under Ar to ensure anhydrous reaction conditions. After cooling the 
reaction mixture to –40 °C, NIS and a catalytic amount of TfOH were added and the 
mixture was stirred at cold for a few hours. TLC analysis of the reaction mixture indicated 
that in addition to the unreacted starting materials 250 and 275b, some products below the 
acceptor 275b and the donor 250 had formed. The reaction was stopped and the newly 
formed products were isolated by flash chromatography. On the basis of 1H NMR analysis, 
the products isolated were not the desired disaccharide 324b. 
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Scheme 77. i) NIS, TfOH (cat.), CH2Cl2, 4Å molecular sieves, -40 °C. 
 
If the amount of acid in the NIS/TfOH-glycosylation process was increased, the amount 
of the unidentified products near the baseline was also increased, but part of the starting 
material remained still unreacted, even if the reaction was performed at rt. It was also 
presumed that the BOC-protection had not remained totally intact under the acidic reaction 
conditions, leading to a partial cleavage of the BOC-protection during the glycosylation. 
Thus, since the reaction did not seem to proceed to completion and there was a danger of 
ending up with a mixture of four different products by the use of acid (an α/β-mixture of 
BOC-disaccharides and non-BOC-disaccharides), the NIS/TfOH method was abandoned. 
Preparation of the disaccharide 324b was attempted also by applying the literature 
procedure published recently,114 employing NBS and TMSOTf. The idea was to replace 
the strong trifluoromethane sulfonic acid by a milder TMSOTf-promoter. However, this 
procedure gave similar results as obtained with the NIS/TfOH-method, affording 
unidentified products along the unreacted starting material. 
Since there were not much of the amino sugar derivatives 275a and 275b left, I decided 
to accomplish the preparation of the target disaccharide by employing the neutral NBS-
activation method. According to the procedure of Nicolaou et al.,113 the thioglycoside 
donor 250 and the α-amino sugar acceptor 275a were combined and azeotropically dried 
with benzene before dissolution in freshly distilled CH2Cl2. After stirring the solution with 
pulverized 4Å molecular sieves under argon atmosphere at rt for 30 min, NBS was added 
and the mixture was allowed to stir at rt for 1.5 h. According to the literature,113 the 
formation of the glycosidic bond should have been completed in 30 min, but TLC analysis 
of the reaction mixture indicated a majority of unreacted acceptor 275a. A large excess of 
both donor 250 and NBS were added to the mixture and stirring was continued for 1 h. 
Since the reaction did not seem to proceed any more, the reaction was stopped and the 
crude product mixture was purified by flash chromatography after aqueous work-up. Since 
the product could not be separated from NBS by flash chromatography, it was purified by 
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preparative layer chromatography to afford 6.5 mg (17 %) of the target disaccharide, 
tentatively assigned as the α-analogue 325 (Scheme 78).  
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Scheme 78. i) NBS, CH2Cl2, 4Å molecular sieves, rt. 
 
The α-stereochemistry of the product 325 was assigned on the basis of the coupling 
constant of 4.8 Hz between the H1- and H2-protons of the xylose fragment (Figure 27). The 
4C1 conformation of the xylose ring was deduced by the coupling constants of JH4,H5eq = 
6.6 Hz and JH4,H5ax = 8.4 Hz; in the case of the 1C4 ring conformation the corresponding 
coupling constants should have been 3-4 Hz. The possible 4C1 and 1C4 conformations and 
the coupling constants measured for compound 325 are shown in Figure 27. The coupling 
constants of JH2,H3 and JH3,H4 could not be determined due to the rotamers. 
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Figure 27. 
 
The stereochemical outcome of the glycosidic bond formed was a bit confusing, since 
the participating acetate functionality in the 2-position of the donor 250 is a 1,2-trans-
directing group and thus, should have produced a β-glycosidic bond as the major product. 
However, it was recently reported of unexpected α-stereochemical outcomes of attempted 
β-glycosylations in the case of acetylated thioglycosides.121 
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4.15. Conclusions 
 
The α-analogue of the disaccharide fragment of pradimicin A was synthesized from the 
commercially available, suitably protected D-xylose derivative and the amino sugar unit, 
prepared from the amino acid L-threonine. L-Threonine was first converted to the fully 
protected L-threoninal according to known procedures. Horner-Emmons-Wadsworth 
olefination of the aldehyde provided the corresponding E-enoate, which after ruthenium-
catalyzed dihydroxylation, followed by acetate protection of the hydroxyl groups, was 
subjected to acid-catalyzed lactonization. Attempts to introduce the N-methyl functionality 
to the molecule at the lactone stage resulted in the formation of a double bond by 
elimination and the replacement of the acetate protection by a methoxy group. Therefore, 
the lactone was transformed to the corresponding fluorides in a two-stage approach; first 
platinum-catalyzed hydrogenation to the corresponding lactols and DAST-fluorination. 
The N-methyl group was then attached to the molecule. In order to prepare for the 
coupling the disaccharide part to be formed to the pradimicin aglycon trans-selectively, the 
C-2-position of the glycosyl fluoride was protected as its benzoyl ester. Regioselective 
benzoylation was accomplished via stannylene derivatives, employing dibutyltin oxide and 
benzoyl chloride. The structures of both the 2-O- and 3-O-monobenzoylated products of 
the β-fluoride were confirmed by crystal structure analysis. The final step in the formation 
of the disaccharide moiety was the coupling of the amino sugar fluoride 275a with the 
protected D-xylose derivative 250. Since the acidic coupling conditions led at least partial 
cleavage of the BOC-protection, the glycosylation was performed under neutral 
conditions, producing the protected disaccharide derivative of pradimicin A, tentatively 
assigned as its α-analogue.  
In conclusion, the amino acid based synthesis to the amino sugar fragment of 
pradimicin A was successfully developed, the amino sugar unit possessing the 
participating benzoyl protection at its C-2-position which is ideal for the intended trans-
glycosylation of the disaccharide fragment and the aromatic aglycon. Preliminary 
glycosylation studies to produce the disaccharide unit of pradimicin were also performed, 
but further examination to adjust the stereoselectivity of the glycosylation is required. 
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5. Experimental 
 
General procedures. Acetonitrile was dried by distillation from phosphorus pentoxide 
and methanol from magnesium methoxide. THF and dimethoxyethane were distilled prior 
to use from sodium/benzophenone ketyl. Toluene, benzene and triethylamine were 
distilled from sodium and dichloromethane from calcium hydride. Boron trifluoride diethyl 
etherate and DMF were distilled under reduced pressure from calcium hydride and stored 
under Ar. Isobutyraldehyde was dried over Na2SO4 and distilled. All other commercial 
reagents were used as obtained from the supplier, without further purification. All air or 
moisture sensitive reactions were performed under an atmosphere of argon with magnetic 
stirring. Oxidations by O2 were performed either in a round-bottomed flask equipped with 
an oxygen balloon or in a glass reactor by bubbling oxygen through a gas inlet in the 
bottom of the reactor. The purity of the oxygen gas was 99.5 %. Oxygen flow was 
controlled by Brooks Mass Flow Meter Model 5850TR. 
Analytical thin layer chromatography (TLC) was performed on Merck silica gel or 
aluminum oxide 60 F254 plates. The TLC plates were visualized by UV light and ninhydrin 
or phosphomolybdic acid (PMA) or anisaldehyde/gl. AcOH/H2SO4/EtOH (5:1:5:90). Flash 
chromatography was performed using Silica gel 60 (E. Merck) as the stationary phase. 
Optical rotations were measured with Perkin Elmer 343 Polarimeter. Melting points 
were determined with Gallenkamp melting point apparatus and are uncorrected. 
NMR spectra were recorded on Bruker 400 (1H 400.130 MHz, 13C 100.613 MHz), 
Bruker 200 (1H 200.13 MHz, 13C 50.32 MHz) or Varian 400 (1H 399.990 MHz, 13C 
100.587 MHz) spectrometer. Chemical shifts are reported in ppm (δ) with respect to the 
scale calibrated to the solvent residual signal or using tetramethylsilane (TMS) as an 
internal standard. 
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Mass spectra were determined by Jeol DX 303/DA 5000, Micromass LCT, Kratos MS 
80 or BioTOF II Electrospray Time-of-Flight mass spectrometer. 
HPLC analyses were performed with a Waters HPLC system using Waters 486 Tunable 
Absorbance Detector and Shandon Hypersil 25cm x 0.46cm column. Gas chromatograms 
were measured by Perkin-Elmer 8420 Capillary Gas Chromatograph (columns: DB-624, 
RTX-Volatiles or OV-1701). 
Elemental analyses were carried out on a Perkin-Elmer 2400 instrument. 
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5.1.  (4S, 5R)-Methyl 3-(N-tert-butoxycarbonyl)-2,2,5-trimethyl-1,3-
oxazolidine-4-carboxylate 327 
 
O N
CO2Me
BOC
Me
HO NH2
CO2H
Me
327326  
 
Acetylchloride (120 mL, 1.68 mol, 200 mol-%) was added dropwise to ice-cold methanol 
(500 mL). After the addition of L-threonine (100 g, 0.84 mol, 100 mol-%) the reaction 
mixture was warmed in an oil bath to 50 °C and stirred at this temperature for 2 days. 
Concentration afforded the crude L-threonine methyl ester hydrochloride as a yellow oil, 
which was used in the next step without further purification. Rf (50 % EtOAc/MeOH, 
ninhydrin) = 0.46. 1H NMR (400 MHz, CD3OD) δ 4.31-4.25 (m, 1H), 3.94 (d, 1H, J = 4.0 
Hz), 3.85 (s, 3H), 1.33 (d, 3H, J = 6.4 Hz). 
The crude ester hydrochloride obtained above was dissolved in a mixture of methanol 
(10 mL) and dichloromethane (500 mL) and the solution was cooled in an ice bath. 
Triethylamine (146 mL, 1.05 mol, 125 mol-%) was added dropwise, followed by addition 
of di-tert-butyl dicarbonate (183 g, 0.84 mol, 100 mol-%). The reaction mixture was 
allowed to warm to rt (evolution of CO2), stirred overnight and quenched with 10 % citric 
acid solution (3 x 175 mL). The organic phase was washed with brine (175 mL), dried 
over MgSO4 and concentrated to give the crude N-BOC-threonine methyl ester as a yellow 
oil (176 g, 90 %), which was employed in the next step without further purification. Rf (50 
% EtOAc/MeOH, ninhydrin) = 0.89. 1H NMR (400 MHz, CD3OD) δ 5.50 (d, 1H, J = 4.0 
Hz), 4.25-4.22 (m, 1H), 4.13 (s, 1H), 3.74 (s, 3H), 1.52-1.51 (m, 1H), 1.46 (s, 9H), 1.19 (d, 
3H, J = 6.4 Hz). 
To a solution of N-BOC-threonine methyl ester (176 g, 0.75 mol, 100 mol-%) in 
CH2Cl2 (320 mL) was added 2,2-dimethoxypropane (186 mL, 1.51 mol, 200 mol-%), 
followed by addition of BF3.OEt2 (4.8 mL, 38 mmol, 5 mol-%). The reaction mixture was 
stirred at rt for 24 h, washed with saturated NaHCO3 (3 x 350 mL) and brine (350 mL), 
dried over MgSO4 and concentrated. The crude product was distilled under reduced 
pressure (~100 oC, 0.5 mmHg) to give the protected ester 327 (167 g, 81 %; 73 % over 
three steps) as a colorless oil. Rf (30 % EtOAc/hex) = 0.83. 1H NMR (400 MHz, CDCl3) δ 
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4.15-4.06 (m, 1H), 3.94, 3.85 (d, 1H, J = 7.9 Hz), 3.71 (s, 3H), 1.59 (s, 3H), 1.54 (s, 3H), 
1.43, 1.35 (s, 9H), 1.34 (d, 3H, J = 6.5 Hz). 13C NMR (100 MHz, CDCl3) δ 171.2, 170.7, 
151.8, 150.9, 95.0, 94.4, 80.7, 80.2, 73.8, 73.5, 66.1, 66.0, 52.2, 52.1, 28.1, 27.8, 26.4, 
23.9, 18.8, 18.7. 
 
5.2.  (4S, 5R) 3-(N-tert-butoxycarbonyl)-2,2,5-trimethyl-4-formyl-1,3-
oxazolidine 40 
 
O N
CHO
BOC
Me
O N
CO2Me
BOC
Me
327 40  
 
To a cooled (–84 °C) solution of compound 327 (15.7 g, 57.4 mmol, 100 mol-%) in dry 
toluene (60 mL) was slowly added 0.1 M DIBAL-H in toluene (98 mL, 97.7 mmol, 170 
mol-%). After the addition was complete the mixture was stirred at –84 °C for 5 minutes 
and quenched by slow addition of cold methanol (23 mL). The resulting white emulsion 
was poured into ice-cold 1 N HCl (350 mL) with stirring over 15 minutes and the aqueous 
mixture was then extracted with EtOAc. The combined organic layers were washed with 
brine, dried over MgSO4 and concentrated to give the crude product as a colorless oil. 
Distillation under reduced pressure (~90 oC, 0.5 mmHg) afforded the pure aldehyde 40 
(8.04 g, 57 %). Rf (40 % EtOAc/hex) = 0.66. 1H NMR (400 MHz, CDCl3) δ 9.43, 9.36 (d, 
1H, J = 3.6 Hz), 4.04 (dq, 1H, J = 8.5 Hz, 6.0 Hz), 3.78, 3.68 (dd, 1H, J = 8.5 Hz, 3.6 Hz), 
1.63 (s, 3H), 1.57, 1.55 (s, 3H), 1.48, 1.40 (s, 9H), 1.34 (d, 3H, J = 6.0 Hz). 13C NMR (100 
MHz, CDCl3) δ 197.5, 150.9, 95.0, 81.4, 71.0, 70.1, 69.9, 28.3, 28.1, 26.2, 25.0, 17.7. 
 
 
 
 
 
 
 
114 
5.3.  [2E,3(4S),(5R)]-Methyl 3-[N-(tert-butoxycarbonyl)-2,2,5-
trimethyl-1,3-oxazolidin-4-yl]propenoate 101 and 
[2Z,3(4S),(5R)]-Methyl 3-[N-(tert-butoxycarbonyl)-2,2,5-
trimethyl-1,3-oxazolidin-4-yl]propenoate 41 
 
O N
Me
BOC
CHO
O N
Me
BOC
CO2Me
O N
Me
BOC
CO2Me
40 101 41  
 
Method 1: Potassium carbonate (0.577 g, 4.17 mmol, 200 mol-%) and 18-crown-6 (1.09 g, 
4.17 mmol, 200 mol-%) were mixed with toluene (7 mL) and stirred at rt for 1 h. After 
cooling the mixture to –10 °C, trimethyl phosphonoacetate (0.40 mL, 2.51 mmol, 120 mol-
%) was added and the mixture was stirred at –10 °C for 40 min. Aldehyde 40 (0.508 g, 
2.09 mmol, 100 mol-%) dissolved in toluene (1 mL) was added and the stirred reaction 
mixture was allowed to warm to rt overnight. The reaction was quenched with 5 % citric 
acid and the two layers were separated. The aqueous layer was extracted with Et2O and the 
combined organic layers were washed with brine, dried over MgSO4 and concentrated. 
The product mixture was purified by flash chromatography (silica, 10 % EtOAc/hex) to 
afford pure E-enoate 101 (0.517 g, 83 %) as a colorless oil.  
Method 2: To a cooled (0 °C) suspension of NaH (460 mg, 60 % in mineral oil, 11.5 
mmol, 115 mol-%,) in THF (30 mL) was added trimethyl phosphonoacetate (1.78 mL, 
11.0 mmol, 110 mol-%) dissolved in THF (3 mL). After stirring the mixture at 0 °C for 1 
h, aldehyde 40 (2.43 g, 10.0 mmol, 100 mol-%) dissolved in THF (7 mL) was added 
dropwise. The reaction was slowly brought to rt and stirring was continued for 1.5 h or 
overnight. The reaction was quenched with 5 % citric acid and the two layers were 
separated. The aqueous layer was extracted with Et2O and the combined organic layers 
were washed with brine, dried over MgSO4 and concentrated to give a mixture of E- and 
Z-enoates (2.86 g, 96 %). An analytical sample of Z-enoate 41 was separated by flash 
chromatography (silica, 10 % EtOAc/hex) to afford pure Z-enoate 41 as a white solid. 
101: Rf (20 % EtOAc/hex) = 0.51. [α]D20 = -27.5 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 6.74-6.71 (m, 1H), 5.89-5.85 (m, 1H), 3.84-3.81 (m, 2H), 3.70 (s, 3H), 1.56 (s, 
3H), 1.48 (s, 3H), 1.41, 1.35 (s, 9H), 1.24 (d, 3H, J = 6.0 Hz). 13C NMR (100 MHz, 
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CDCl3) δ 166.2, 151.6, 147.4, 121.8, 94.5, 80.3, 74.4, 65.1, 51.5, 28.3, 28.2, 26.3, 25.3, 
17.1. 
41: Rf (20 % EtOAc/hex) = 0.57. Mp. 77-78 °C, lit.34 mp. 76-78 °C. [α]D20 = +72.0 (c = 
1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.02-5.97 (m, 1H), 5.86 (d, 1H, J = 11.4 Hz), 
5.16-5.08 (m, 1H), 3.84 (m, 1H), 3.69 (s, 3H), 1.60 (s, 3H), 1.51 (s, 3H), 1.44, 1.35 (s, 
9H), 1.32 (d, 3H, J = 6.1 Hz). 13C NMR (100 MHz, CDCl3) δ 166.1, 151.9, 149.0, 120.3, 
94.4, 79.9, 75.1, 60.8, 51.2, 28.3, 28.1, 26.5, 25.7, 17.7. 
 
5.4. [2R,3S,3(4S),(5R)]-Methyl 3-[N-(tert-butoxycarbonyl)-2,2,5-
trimethyl-1,3-oxazolidin-4-yl]-2,3-dihydroxypropanoate 269a 
and [2S,3R,3(4S),(5R)]-Methyl 3-[N-(tert-butoxycarbonyl)-2,2,5-
trimethyl-1,3-oxazolidin-4-yl]-2,3-dihydroxypropanoate 269b 
 
CO2Me
O
N
BOC
CO2Me
O
N
OH
OH
BOC
CO2Me
O
N
OH
BOC
OH
Me Me Me
101 269a 269b  
 
To a vigorously stirred solution of E-enoate 101 (1.67 g, 5.58 mmol, 100 mol-%) in 
EtOAc/CH3CN (33 ml/33 mL) at 0-5 °C (ice/water bath) was added a solution of 
RuCl3.x(H2O) (81 mg, 0.39 mmol, 7 mol-%) and NaIO4 (1.79 g, 8.37 mmol, 150 mol-%) 
in distilled water (11 mL). The two-phase mixture was stirred vigorously for 3 min and 
quenched with a saturated aqueous solution of Na2S2O3 (55 mL). The aqueous phase was 
separated and extracted with EtOAc (3 x 85 mL). The combined organic layers were 
washed with brine (85 mL), dried over MgSO4 and concentrated to afford a mixture of 
diols 269a and 269b. The diols were separated by flash chromatography (silica, 30 % 
EtOAc/hex) to give diol 269a (0.90 g, 48 %) and diol 269b (0.33 g, 18 %) as a colorless 
oil. 
269a: Rf (50 % EtOAc/hex) = 0.31. [α]D20 = -15.4 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
DMSO) δ 5.16 (d, 2H, J = 7.7 Hz), 4.41 (dq, 1H, J = 6.4 Hz, 3.8 Hz), 4.13 (td, 1H, J = 7.7 
Hz, 2.9 Hz), 4.04-3.99 (m, 1H), 3.64 (s, 3H), 3.54 (bs, 1H), 1.50 (s, 3H), 1.41, 1.39 (s, 
12H), 1.22 (d, 3H, J = 6.2 Hz). 13C NMR (100 MHz, DMSO) δ 173.6, 93.7, 80.0, 73.1, 
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71.6, 66.9, 60.4, 52.3, 28.7, 27.5, 22.4, 21.4, 14.8. HRMS: m/z calcd for C15H27NO7 (M-
Me)+ 318.1553, found 318.1568. 
269b: Rf (50 % EtOAc/hex) = 0.45. [α]D20 = -35.3 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
DMSO) δ 5.26 (d, 1H, J = 7.9 Hz), 4.75-4.74 (m, 1H), 4.51 (m, 1H), 4.21 (m, 1H), 4.12 (d, 
1H, J = 6.4 Hz), 3.67 (s, 1H), 3.64 (s, 3H), 1.49 (s, 3H), 1.41 (s, 12H), 1.20 (d, 3H, J = 6.2 
Hz). 13C NMR (100 MHz, DMSO) δ 174.1, 94.2, 80.1, 73.0, 71.0, 65.7, 60.4, 52.3, 28.6, 
22.5, 21.4, 14.8. HRMS: m/z calcd for C15H27NO7 (M+1)+ 334.1866, found 334.1827. 
 
5.5. [2R,2(4S),(5S),(6R)]-Methyl 5-[N-(tert-butoxycarbonyl)-2,2,6-
trimethyl-1,3-dioxan-4-yl]ethanoate 280 
 
O O
CO2Me
NH OH
O
N
CO2Me
OH
OH
Me
BOC
Me
280269a
BOC
 
 
Method 1: To a solution of 269a (384 mg, 1.15 mmol, 100 mol-%) in CH2Cl2 (10 mL) was 
added (1S)-(+)-10-camphorsulfonic acid (40 mg, 0.173 mmol, 15 mol-%). After stirring 
the reaction mixture at rt for 24 hours, saturated NaHCO3 was added and the aqueous layer 
was extracted with Et2O. The combined organic layers were dried over Na2SO4 and 
concentrated. The crude product mixture was purified by flash chromatography (silica, 30 
% EtOAc/hex) to give compound 280 (68 mg, 18 %) as a colorless oil. 
Method 2: A solution of compound 269a (95 mg, 0.28 mmol, 100 mol-%) in glacial acetic 
acid (0.85 mL) was stirred at 60 °C for 1 day. The reaction was quenched by evaporating 
acetic acid and dichloromethane was added. The organic layer was washed with saturated 
NaHCO3 and brine, dried over Na2SO4 and concentrated. An analytical sample of 
compound 280 was purified by flash chromatography (silica, 30 % EtOAc/hex). 
Rf (50 % EtOAc/hex) = 0.48. [α]D20 = +0.4 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 4.81 (d, 1H, J = 10.4 Hz), 4.31 (dd, 1H, J = 8.3 Hz, 2.1 Hz), 4.22-4.16 (m, 1H), 
4.04 (dq, 1H, J = 6.6 Hz, 4.8 Hz), 3.75 (s, 3H), 3.65 (dd, 1H, J = 7.9 Hz, 2.1 Hz), 3.10 (d, 
1H, J = 8.3 Hz), 1.40 (s, 9H), 1.28 (s, 3H), 1.24 (s, 3H), 1.10 (d, 3H, J = 6.6 Hz). 13C NMR 
(100 MHz, CDCl3) δ 172.7, 155.8, 101.1, 79.6, 74.4, 70.7, 66.2, 52.4, 51.5, 28.2, 24.3, 
23.5, 15.0. HRMS: m/z calcd for C15H27NO7 (M+Na)+ 356.1685, found 356.1667. 
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5.6. [2R,3S,3(4S),(5R)]-Methyl 3-[N-(tert-butoxycarbonyl)-2,2,5-
trimethyl-1,3-oxazolidin-4-yl]-2,3-diacetoxypropanoate 270 
 
CO2Me
O
N
OH
OH
BOC
CO2Me
O
N
OAc
OAc
BOC
Me Me
269a 270  
 
To a solution of 269a (986 mg, 2.96 mmol, 100 mol-%) in dichloromethane (60 mL) were 
added pyridine (6 mL), acetic anhydride (5.61 mL, 59.1 mmol, 2000 mol-%) and 4-
dimethylaminopyridine (60 mg, 49.1 mmol, 17 mol-%). The reaction mixture was stirred 
at rt for 30 min and washed with distilled water (2 x 15 mL) and brine (15 mL). Drying 
over MgSO4 and concentration afforded the crude 270, which was purified by flash 
chromatography (silica, 30 % EtOAc/hex) to give compound 270 (1.22 g, 99 %) as a 
colorless oil. Rf (50 % EtOAc/hex) = 0.75. [α]D20 = -54.5 (c = 1.00, CHCl3). 1H NMR (400 
MHz, CDCl3) δ 5.76 (bs, 1H), 5.05 (d, 1H, J = 2.6 Hz), 4.36 (bs, 1H), 3.73 (s, 3H), 2.18 (s, 
3H), 2.08 (s, 3H), 1.59 (s, 3H), 1.48 (s, 9H), 1.43 (s, 3H), 1.33 (d, 3H, J = 6.6 Hz). 13C 
NMR (100 MHz, CDCl3) δ 169.9, 169.6, 167.7, 94.3, 81.0, 72.0, 71.7, 70.1, 64.3, 52.6, 
28.2, 21.9, 20.6, 20.4, 14.1. HRMS: m/z calcd for C19H31NO9 (M-Me)+ 402.1764, found 
402.1761. 
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5.7. (3R,4S,5S,6R)-3,4,5,6-Tetrahydro-3,4-diacetoxy-5-(N-tert-
butoxycarbonyl)amino-6-methyl-2-pyrone 271 
 
CO2Me
O
N
OAc
OAc
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NHBOC
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OAc
Me
271270  
 
Compound 270 (320 mg, 0.77 mmol, 100 mol-%) dissolved in glacial acetic acid (2.3 mL) 
was stirred at 60 °C for 7 days. Acetic acid was evaporated and the precipitate was 
dissolved in ethyl acetate (30 mL), washed with saturated NaHCO3 (3 x 30 mL), dried over 
Na2SO4 and concentrated. Purification by flash chromatography (silica, 20 % EtOAc/hex) 
afforded the lactone 271 (140 mg, 51 %; corrected yield 68 %, based on recovered starting 
material) as a white, soft solid. Rf (30 % EtOAc/hex) = 0.33. Mp. 114-115 °C. [α]D20 = 
+125.1 (c = 1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.29 (dd, 1H, J = 10.3 Hz, 4.0 
Hz), 5.19 (d, 1H, J = 10.1 Hz), 4.87 (d, 1H, J = 9.2 Hz), 4.74 (q, 1H, J = 12.6 Hz, 6.4 Hz), 
4.46-4.43 (m, 1H), 2.17 (s, 3H), 2.06 (s, 3H), 1.46 (s, 9H), 1.41 (d, 3H, J = 6.4 Hz). 13C 
NMR (100 MHz, CDCl3) δ 170.3, 170.2, 166.5, 155.9, 80.4, 74.9, 71.0, 68.7, 51.1, 28.2, 
20.7, 20.5, 16.6. HRMS: m/z calcd for C15H23NO3 (M+Na)+ 368.1321, found 368.1326. 
 
5.8. Oxidation of cyclohexene 284 in the presence of 
isobutyraldehyde 
 
O
284 285 287
O
 
 
General procedure: Cyclohexene (205 mg, 2.5 mmol, 100 mol-%), isobutyraldehyde (360 
mg, 5.0 mmol, 200 mol-%) and a catalyst, if used, were dissolved in acetonitrile (25 mL) 
under an atmosphere of oxygen. The amount of the cobalt catalyst was 5 mol-% or 0.13 
mol-%. The solution was stirred at rt overnight or for several days producing cyclohexene 
oxide 285 as the main product, 2-cyclohexen-1-ol 286 and 2-cyclohexen-1-one 287. 
119 
Isobutyric acid was formed as a by-product. The ratio of epoxide to ketone was dependent 
on the catalyst used and the amount of the catalyst. The products were identified by GC 
and GC/MS analysis by comparing to the authentic samples. 
 
5.9. Oxidation of cyclohexene 284 to 2-cyclohexen-1-ol 286 and 2-
cyclohexen-1-one 287 
 
284 286
OH
+
287
O
 
 
In a typical experiment, a round-bottomed flask equipped with a reflux condenser and an 
oxygen balloon was charged with cyclohexene (4.0 g, 49.0 mmol, 100 mol-%) and 
Co(py)2Br2 (24 mg, 0.06 mmol, 0.13 mol-%). The reaction mixture was stirred under 
oxygen at 50 °C for 18 h affording 4 % of 2-cyclohexen-1-ol 286 and 7 % of 2-
cyclohexen-1-one 287. The progress of the reaction was followed by gas chromatography. 
The products were determined by GC and GC/MS analysis by comparison to authentic 
samples. 
 
5.10. Epoxidation of α-pinene 291 to α-pinene oxide 292 
 
291 292
O
 
 
α-Pinene 291 (272 mg, 2.0 mmol, 100 mol-%) and isobutyraldehyde (288 mg, 4.0 mmol, 
200 mol-%) were dissolved in acetonitrile (10 mL) in a round-bottomed flask. The reaction 
was stirred under an atmosphere of oxygen at rt for 6 h affording α-pinene oxide as the 
sole product. After evaporating the solvent, the residue was dissolved in ethyl acetate (15 
mL) and washed with saturated NaHCO3 and brine. Drying over Na2SO4 and concentration 
gave the crude product, which was purified by flash chromatography (neutral aluminium 
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oxide, hex:EtOAC 40:1) to yield α-pinene oxide 292 (209 mg, 1.38 mmol, 69 %) as a 
colorless liquid. The product was identified by comparison of its NMR spectra to the 
literature.122  
 
5.11. Allylic oxidation of α-pinene 291 
 
291 293 294
OOH
 
 
General procedure: Oxidation of α-pinene was performed in an open glass reactor by 
bubbling oxygen through a gas inlet in the bottom of the reactor. α-Pinene (10.0 g, 0.074 
mol, 100 mol-%) and a catalyst were weighed in the reactor and the flow of oxygen was 
set at 5 mL/min by a mass flow meter. Oxidation was continued at 70 °C for several days. 
 
5.12. 1,3-Bis(bromomethyl)-pyridine 297 
 
N N
BrBr
297296  
 
2,6-Lutidine (2.70 g, 25.0 mmol, 100 mol-%) and NBS (11.1 g, 62.5 mmol, 250 mol-%) 
were mixed in 100 mL of benzene in a round-bottomed flask and AIBN (0.9 g) was added. 
The mixture was heated at reflux under illumination (150 W bulb) for 22 hours. The 
reaction mixture was cooled to rt and filtered. The filtrate was collected and the solvent 
evaporated. The product was extracted from the residue with boiling hexanes. The crude 
product was recrystallized from hexane to give compound 297 (1.66 g, 6.27 mmol, 25 %) 
as white crystals, mp. 82-84 °C. 1H NMR (200 MHz, CDCl3) δ 7.71 (dd, 1H, J = 8.0 Hz, 
7.4 Hz), 7.37 (d, 2H, J = 7.7 Hz), 4.54 (s, 4H). 13C NMR (50 MHz, CDCl3) δ 156.8, 138.1, 
122.7, 33.4. Anal. calcd for C7H7NBr2 C 31.7, H 2.7, N 5.3, found C 32.4, H 2.8, N 5.4. 
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5.13. 1,3-Bis[(pyrrolidinyl-N-)methyl]-pyridine 298 
 
N
BrBr
297
N
NN
298  
 
A solution of 1,3-bis(bromomethyl)-pyridine 297 (795 mg, 3.0 mmol, 100 mol-%) in 
benzene (20 mL) was added dropwise to a cooled (ice bath) and stirred solution of 
pyrrolidine (1.25 mL, 15 mmol, 500 mol-%) in benzene (8 mL). The mixture was stirred at 
rt for 1 h. After removing the solvent under reduced pressure diethyl ether (10 mL) and 
Et3N (1.5 mL) were added. The solid was filtered off, washed with diethyl ether (5 mL) 
and the filtrate was evaporated. The residue was distilled by Kugelrohr to give compound 
298 as a yellowish oil (54 mg, 2.2 mmol, 74 %). 1H NMR (200 MHz, CD3OD) δ 7.82 (dd, 
1H, J = 7.9 Hz, 7.7 Hz), 7.43 (d, 2H, J = 7.7 Hz), 3.82 (s, 4H), 2.65 (m, 8H), 1.86 (m, 8H). 
13C NMR (50 MHz, CD3OD) δ 159.1, 138.8, 123.2, 62.5, 55.1, 24.3. HRMS: m/z calcd for 
C15H24N3 MH+ 246.1970, found 246.1999. 
 
5.14. 1,3-Bis[(pyrrolidinyl-N-)methyl]-pyridine cobalt complex 299 
 
N
NN
N
NN Co
ONO2O2NO
299298  
 
A solution of 1,3-bis[(pyrrolidinyl-N-)methyl]-pyridine 298 (245 mg, 1.0 mmol, 100 mol-
%) and cobalt(II) nitrate hexahydrate (291 mg, 1.0 mmol, 100 mol-%) in absolute ethanol 
was stirred at rt overnight to form a purple solid. The solvent was filtered off and the solid 
washed with cold hexane affording a crude complex as a purple powder (360 mg, 0.8 
mmol, 84 %). After analyses, the product remained (313 mg) was purified by 
crystallization from absolute EtOH yielding complex 299 (256 mg, 0.6 mmol, 69 %) as 
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purple crystals, mp. 192-193 °C. Anal. calcd for C15H23N5O6Co C 42.1, H 5.4, N 16.4, 
found C 42.1, H % 5.0, N 16.3. 
 
5.15. (5S,6R)-5,6-Dihydro-3-methoxy-5-(N-tert-butoxycarbonyl-N-
methyl)amino-6-methyl-2-pyrone 300 
 
O
OAc
OAc
NHBOC
Me
O
NHBOC
Me
O O
OMe
271 300  
 
To a mixture of NaH (18 mg, 0.45 mmol, 155 mol-%; 60 % in mineral oil) and THF (5 
mL) was added a solution of lactone 271 (100 mg, 0.29 mmol, 100 mol-%) in THF (2 mL) 
at 0 °C (ice-bath). After stirring the reaction mixture at rt for 45 min, MeI (45 µl, 0.72 
mmol, 250 mol-%) was added at 0 °C and the mixture was stirred at rt overnight. The 
reaction was quenched with 1 M NH4Cl (5 mL) and the solution was extracted with ether 
(25 mL). The combined organic layers were washed with water and brine, dried over 
Na2SO4 and evaporated to produce compound 300 and an unidentified product. An 
analytical sample of compound 300 was purified by flash chromatography (silica, 20 % 
EtOAc/hex). 
Rf (30 % EtOAc/hex) = 0.25. 1H NMR (400 MHz, CDCl3) δ 5.73 (d, 1H, J = 6.8 Hz), 4.66 
(qd, 2H, J = 6.6 Hz, 3.0 Hz), 4.43 (ddd, 1H, J = 9.8 Hz, 6.8 Hz, 3.0 Hz), 3.68 (s, 3H), 1.45 
(s, 9H), 1.39 (d, 3H, J = 6.6 Hz). 13C NMR (100 MHz, CDCl3) δ 160.8, 155.2, 146.5, 
108.3, 80.4, 76.9, 55.6, 46.5, 28.3, 16.3. HRMS: m/z calcd for C12H19NO5 (M+Na)+ 
280.1161, found 280.1186. 
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5.16. (5S,6R)-5,6-Dihydro-3-acetoxy-5-(N-tert-butoxycarbonyl-N-
methyl)amino-6-methyl-2-pyrone 303 and (5S,6R)-5,6-Dihydro-
3-methoxy-5-(N-tert-butoxycarbonyl-N-methyl)amino-6-methyl-
2-pyrone 304 
 
O
OAc
OAc
NHBOC
Me
O
NMeBOC
O
NMeBOC
Me
O O O
OAc OMe
Me
271 303 304  
 
MeI (3.5 mL, 56 mmol, 100-fold excess) and Ag2O (400 mg, 1.73 mmol, 310 mol-%) 
were added to a solution of 271 (193 mg, 0.56 mmol, 100 mol-%) in DMF (6 mL). The 
reaction was protected from light and stirred at rt overnight. The reaction mixture was 
filtered through a pad of Celite and rinsed with EtOAc. Water was added and the aqueous 
layer extracted with EtOAc. The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated. Purification by flash chromatography (silica, 20 % 
EtOAc/hex) afforded compounds 303 (38 mg, 21 %) and 304 (92 mg, 56 %) as white 
amorphous solids. 
303 (contains a small amount of 304): Rf (30 % EtOAc/hex) = 0.40. 1H NMR (400 MHz, 
CDCl3) δ 6.33 (d, 1H, J = 6.5 Hz), 5.18 (dd, 1H, J = 6.5 Hz, 4.4 Hz), 4.81 (dq, 1H, J = 6.6 
Hz, 4.4 Hz), 2.80 (s, 3H), 2.30 (s, 3H), 1.50 (s, 9H), 1.38 (d, 3H, J = 6.6 Hz). 13C NMR 
(100 MHz, CDCl3) δ 168.4, 159.5, 155.9, 141.3, 126.8, 80.9, 77.1, 49.7, 30.5, 28.2, 20.4, 
15.8. HRMS: m/z calcd for C14H21NO6 (M+Na)+ 322.1267, found 322.1253. 
304 (contains a small amount of 303): Rf (30 % EtOAc/hex) = 0.18. 1H NMR (400 MHz, 
CDCl3) δ 5.51 (d, 1H, J = 6.8 Hz), 5.09 (dd, 1H, J = 6.8 Hz, 4.1 Hz), 4.66 (qd, 1H, J = 6.7 
Hz, 4.1 Hz), 3.71 (s, 3H), 2.73, 2.69 (s, 3H), 1.47 (s, 9H), 1.33 (d, 3H, J = 6.7 Hz). 13C 
NMR (100 MHz, CDCl3) δ 160.9, 156.0, 148.1, 106.1, 80.5, 74.2, 55.7, 49.5, 30.1, 28.3, 
16.0. HRMS: m/z calcd for C13H21NO5 (M+Na)+ 294.1317, found 294.1323. 
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5.17. 2,3-Di-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl)amino-α-
D-galactopyranose 272a and 2,3-Di-O-acetyl-4,6-dideoxy-4-(N-
tert-butoxycarbonyl)amino-β-D-galactopyranose 272b 
 
O
NHBOC
AcO O
O
NHBOC
AcO
OH
O
NHBOC
AcO OH
AcO AcO AcO
271 272a 272b  
 
In a two-necked round-bottomed flask was placed EtOAc (2.5 mL) and PtO2 (85 mg, 0.31 
mmol, 32 mol-%). PtO2 was reduced to Pt by filling the flask with hydrogen and stirring 
the mixture for 15 min at rt. Lactone 271 (340 mg, 0.98 mmol, 100 mol-%) dissolved in 
EtOAc (3 mL) was added and stirring was continued for 6 hours under an atmosphere of 
hydrogen. The reaction mixture was filtered through a pad of Celite and the solvent was 
evaporated under reduced pressure to afford 1:1 mixture of lactols 272a and 272b (260 
mg, 76 %) as a white solid. The anomers were separated from each other by crystallization 
from EtOAc/hex. 
272a (contains a small amount of 272b): Rf (50 % EtOAc/hex) = 0.33. 1H NMR (400 
MHz, CDCl3) δ 5.40 (t, 1H, J = 3.7 Hz), 5.26 (dd, 1H, J = 10.9 Hz, 4.0 Hz), 4.95-4.89 (m, 
2H), 4.47 (dq, 1H, J = 6.5 Hz, 1.6 Hz), 4.17 (ddd, 1H, J = 10.1 Hz, 4.0 Hz, 1.6 Hz), 3.39 
(dd, 1H, J = 3.7 Hz), 2.10 (s, 3H), 2.00 (s, 3H), 1.44 (s, 9H), 1.17 (d, 3H, J = 6.5 Hz). 13C 
NMR (100 MHz, CDCl3) δ 170.7, 170.4, 156.1, 90.3, 79.6, 68.9, 68.8, 64.2, 52.4, 28.2, 
20.9, 16.4. HRMS: m/z calcd for C15H25NO8 (M+Na)+ 370.1478, found 370.1474. 
272b: Rf (50 % EtOAc/hex) = 0.28. Mp. 166-168 oC. [α]D20 = + 28.4 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 5.10 (d, 1H, J = 9.5 Hz), 4.95-4.93 (m, 2H), 4.63 (t, 1H, J = 
7.3 Hz), 4.15 (qd, 1H, J = 10.1 Hz, 3.5 Hz, 1.5 Hz), 4.00 (bs, 1H), 3.84 (dq, 1H, J = 6.4 
Hz, 1.5 Hz), 2.10 (s, 3H), 2.01 (s, 3H), 1.44 (s, 9H), 1.26 (d, 3H, J = 6.4 Hz). 13C NMR 
(100 MHz, CDCl3) δ 171.4, 170.5, 156.1, 96.0, 79.7, 72.0, 71.4, 70.0, 51.9, 28.3, 20.9, 
20.8, 16.3. HRMS: m/z calcd for C15H25NO8 (M+Na)+ 370.1478, found 370.1471. 
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5.18. 2,3-Di-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl)amino-α-
D-galactopyranosyl fluoride 273a and 2,3-Di-O-acetyl-4,6-
dideoxy-4-(N-tert-butoxycarbonyl)amino-β-D-galactopyranosyl 
fluoride 273b 
 
O
NHBOC
AcO
O
NHBOC
AcO
F
O
NHBOC
AcO F
OHAcO AcO AcO
272 273a 273b  
 
General procedure: Lactol 272 (3.09 g, 8.89 mmol, 100 mol-%) dissolved in dry THF (35 
mL) was cooled to 0 oC and DAST (1.76 mL, 13.3 mmol, 150 mol-%) was added. The 
cooling bath was removed and the reaction mixture was stirred at rt for 30 min. After 
cooling the reaction to 0 oC MeOH (0.6 mL) was added and the reaction mixture was 
poured into ice-cold water (20 mL). Extraction with EtOAc (3 x 20 mL), drying over 
Na2SO4 and evaporation afforded the crude mixture of fluorides, which were separated by 
flash chromatography (silica, 10 % EtOAc/hex) to yield the α-anomer 273a (0.70 g, 23 %) 
and the  β-anomer 273b (1.72 g, 55 %) as white solids. 
273a: Rf (30 % EtOAc/hex) = 0.47. Mp. 119-121 oC. [α]D20 = +86.5 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 5.69 (dd, 1H, J = 54 Hz, 3.0 Hz), 5.22 (dd, 1H, J = 10.9 Hz, 
4.0 Hz), 4.96 (ddd, 1H, J = 24 Hz, 10.9 Hz, 3.0 Hz), 4.79 (d, 1H, J = 9.9 Hz), 4.38 (dq, 1H, 
J = 6.5 Hz, 1.5 Hz), 4.25 (ddd, 1H, J = 9.9 Hz, 4.0 Hz, 1.5 Hz), 2.11 (s, 3H), 2.02 (s, 3H), 
1.44 (s, 9H), 1.23 (d, 3H, J = 6.5 Hz). 13C NMR (100 MHz, CDCl3) δ 170.6, 170.2, 155.9, 
104.0 (JCF = 228 Hz), 79.9, 68.6, 67.8 (JCF = 25 Hz), 67.3 (JCF = 4 Hz), 51.8, 28.2, 20.8, 
20.7, 16.2. HRMS: m/z calcd for C15H24FNO7 (M+Na)+ 372.1435, found 372.1436. 
273b: Rf (30 % EtOAc/hex) = 0.31. Mp. 105-107 oC. [α]D20 = +18.1 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 5.18 (dd, 1H, J = 35 Hz, 7.3 Hz), 5.12-5.08 (m, 1H), 4.92 (dd, 
1H, J = 10.3 Hz, 4.3 Hz), 4.86 (d, 1H, J = 10.2 Hz), 4.16 (qd, 1H, J = 10.2 Hz, 4.3 Hz, 1.7 
Hz), 3.89 (q, 1H, J = 6.4 Hz), 2.09 (s, 3H), 2.00 (s, 3H), 1.44 (s, 9H), 1.31 (d, 3H, J = 6.4 
Hz). 13C NMR (100 MHz, CDCl3) δ 170.3, 169.5, 155.8, 107.4 (JCF = 216 Hz), 79.9, 71.5 
(JCF = 11 Hz), 70.3 (JCF = 4 Hz), 69.1 (JCF = 25 Hz), 51.3, 28.2, 20.7, 16.2. HRMS: m/z 
calcd for C15H24FNO7 (M+Na)+ 372.1435, found 372.1432. 
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5.19. 2,3-Di-O-methyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)amino-D-galactopyranosyl fluoride 310 
 
O
NHBOC
AcO
O
NHBOC
MeO
F FAcO MeO
273 310  
 
A solution of compound 273 (19 mg, 0.05 mmol, 100 mol-%) in THF (1 ml) was added to 
a mixture of NaH (7 mg, 0.18 mmol, 320 mol-%; 60 % in oil) and THF (2.5 ml) at 0 °C 
(ice-bath). After stirring the mixture at rt for 45 min, the reaction was cooled to 0 °C and 
MeI (0.1 mL, 1.60 mmol, 3000 mol-%) was added. After stirring the reaction mixture at rt 
overnight 1 M NH4Cl was added and the solution was extracted with ether. The combined 
organic layers were washed with water and brine, dried over Na2SO4 and evaporated to 
give crude 310 as a mixture of α- and β-anomers. 1H NMR (400 MHz, CDCl3) δ 5.79-5.58 
(dd, 1H, J = 53 Hz, 3.0 Hz), 5.13 (m, 1H), 5.0 (m, 1H), 4.8 (m, 1H), 4.57 (m, 1H), 4.20 (m, 
1H, J = 6.6 Hz), 3.57, 3.55 (s, 3H), 3.45, 3.44 (s, 3H), 1.46 (s, 9H), 1.23 (d, 3H, J = 6.4 
Hz). 
 
5.20. 2,3-Di-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)amino-α-D-galactopyranosyl fluoride 274a 
 
O
NHBOC
AcO
AcO
O
NMeBOC
AcO
AcO
FF
273a 274a  
 
MeI (16.4 mL, 263 mmol, 200-fold excess) and Ag2O (0.915 g, 3.95 mmol, 300 mol-%) 
were added to a solution of 273a (0.460 g, 1.32 mmol, 100 mol-%) in DMF (15 mL). The 
reaction was protected from light and stirred at rt for 2 hours. The reaction mixture was 
filtered through a pad of Celite and rinsed with CH2Cl2. Water was added and the aqueous 
layer was extracted with CH2Cl2. Drying over MgSO4, filtration and evaporation afforded 
the crude product mixture which was purified by flash chromatography (silica, 10 % 
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EtOAc/hex) to give compound 274a (202 mg, 42 %) as a colorless oil. Rf (20 % 
EtOAc/hex) = 0.39. [α]D20 = +71.5 (c = 1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.75, 
5.72 (dd, 1H, J = 53 Hz, 3.1 Hz), 5.46, 5.33 (dd, 1H, J = 11.3 Hz, 5.8 Hz), 5.22, 5.17 (ddd, 
1H, J = 23 Hz, 11.3 Hz, 3.1 Hz), 4.71 (dd, 1H, J = 5.8 Hz, 3.4 Hz), 4.44, 4.38 (dq, 1H, J = 
6.7 Hz, 3.4 Hz), 3.03, 3.02 (s, 3H), 2.07, 2.06 (s, 3H), 2.01, 1.96 (s, 3H), 1.42, 1.38 (s, 
9H), 1.23, 1.20 (d, 3H, J = 6.7 Hz). 13C NMR (100 MHz, CDCl3) δ 170.4, 170.2, 169.6, 
169.5, 156.90, 156.2, 104.4 (JCF = 227 Hz), 104.2 (JCF = 228 Hz), 80.4, 79.9, 67.9 (JCF = 4 
Hz), 67.6 (JCF = 11 Hz), 67.2 (JCF = 20 Hz), 54.1, 53.4, 33.1, 32.4, 28.2, 28.1, 20.7, 20.6, 
16.1, 16.0. HRMS: m/z calcd for C16H26FNO7 (M+Na)+ 386.1591, found 386.1586. 
 
5.21. 2,3-Di-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)amino-β-D-galactopyranosyl fluoride 274b 
 
O
NHBOC
AcO
AcO
O
NMeBOC
AcO
AcO
F F
273b 274b  
 
MeI (35 mL, 0.56 mol, 200-fold excess) and Ag2O (1.96 g, 8.45 mmol, 300 mol-%) were 
added to a solution of 273b (0.984 g, 2.82 mmol, 100 mol-%) in DMF (40 mL). The 
reaction was protected from light and stirred at rt for 4 hours. The reaction mixture was 
filtered through a pad of Celite and rinsed with CH2Cl2. Water was added and the aqueous 
layer was extracted with CH2Cl2. Drying over MgSO4, filtration and evaporation afforded 
the crude product mixture which was purified by flash chromatography (silica, 10 % 
EtOAc/hex) to give compound 274b (0.470 g, 46 %) as a colorless oil. Rf (20 % 
EtOAc/hex) = 0.31. [α]D20 = +3.3 (c = 1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.47-
5.31 (m, 1H), 5.27-5.00 (m, 2H), 4.68-4.59 (m, 1H), 4.02-3.94 (m, 1H), 3.10 (s, 3H), 2.08, 
2.07 (s, 3H), 2.02, 1.98 (s, 3H), 1.44, 1.39 (s, 9H), 1.32, 1.30 (d, 3H, J = 6.5 Hz). 13C NMR 
(100 MHz, CDCl3) δ 169.7, 169.6, 169.3, 157.0, 156.1, 107.7 (JCF = 215 Hz), 80.4, 80.0, 
71.4 (JCF = 4 Hz), 71.3 (JCF = 4 Hz), 70.8 (JCF = 12 Hz), 70.3 (JCF = 12 Hz), 69.4 (JCF = 24 
Hz), 69.2 (JCF = 24 Hz), 54.6, 53.6, 33.1, 32.5, 28.2, 20.6, 20.5, 16.2. HRMS: m/z calcd 
for C16H26FNO7 (M+Na)+ 386.1591, found 386.1613. 
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5.22. 1,2,3-Tri-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl)amino-
D-galactopyranose 314 
 
O
NHBOC
AcO
O
NHBOC
AcO
OH OAcAcO AcO
272 314  
 
Acetic anhydride (0.14 mL, 1.4 mmol, 1000 mol-%) and DMAP (2.6 mg, 22 µmol, 15 
mol-%) were added to a solution of 272 (50 mg, 0.14 mmol, 100 mol-%) in CH2Cl2 (3 
mL). The reaction was stirred at rt for 30 min and the solvent was evaporated. The crude 
product was directly chromatographed (silica, 30 % EtOAc/hex) to afford a mixture of α- 
and β-anomers 314 (54 mg, 96 %) as a white solid. Rf (50 % EtOAc/hex) = 0.70. 1H NMR 
(400 MHz, CDCl3) δ 6.24, (d, 1H, J = 3.8 Hz), 5.58 (d, 1H, J = 8.2 Hz), 5.20 (dd, 1H, J = 
11.0 Hz, 3.8 Hz), 5.11 (m, 2H), 4.94 (dd, 1H, J = 10.4, 4.3 Hz), 4.88 (d, 1H, J = 9.9 Hz), 
4.84 (d, 1H, J = 10.1 Hz), 4.31 (dq, 1H, J = 6.5 Hz, 1.5 Hz), 4.21 (ddd, 1H, J = 9.9 Hz, 3.8 
Hz, 1.5 Hz), 4.14 (ddd, 1H, J = 10.1 Hz, 4.3 Hz, 1.2 Hz), 3.90 (dq, 1H, J = 6.3 Hz, 1.2 
Hz), 2.11 (s, 3H), 2.07 (s, 3H), 2.00 (s, 12H), 1.43 (s, 18H), 1.23 (d, 3H, J = 6.3 Hz), 1.17 
(d, 3H, J = 6.5 Hz). 13C NMR (100 MHz, CDCl3) δ 170.4, 170.2, 169.6, 169.0, 156.0, 
155.8, 92.5, 89.6, 79.7, 72.3, 70.8, 68.9, 68.2, 67.4, 66.7, 52.0, 51.6, 28.2, 20.8, 20.7, 20.6, 
20.5, 16.3, 16.2. HRMS: m/z calcd for C17H27NO9 (M+Na)+ 412.1584, found 412.1588. 
 
5.23. 1,2,3-Tri-O-acetyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)amino-D-galactopyranose 316 
 
O
NHBOC
AcO
O
NMeBOC
AcO
OAc OAcAcO AcO
314 316  
 
MeI (2.2 mL, 35.3 mmol, 200-fold excess) and Ag2O (125 mg, 0.54 mmol, 300 mol-%) 
were added to a solution of 314 (70 mg, 0.18 mmol, 100 mol-%) in DMF (2.5 mL). The 
reaction was protected from light and stirred at 50 oC overnight. The reaction mixture was 
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filtered through a pad of Celite and rinsed with EtOAc. Water was added and the aqueous 
layer was extracted with EtOAc. Drying over Na2SO4, filtration and evaporation afforded a 
mixture of product 316 and the starting material 314 which could not be separated from 
each other by flash chromatography. 
 
5.24. Attempted thioglycosylation for 314 
 
O
NHBOC
AcO
O
NHBOC
AcO
OAc SPhAcO AcO
314 317
x
 
 
Thiophenol (16 µL, 0.15 mmol, 120 mol-%) and BF3.OEt2 (24 µL, 0.19 mmol, 150 mol-
%) were added to a solution of compound 314 (50 mg, 0.13 mmol, 100 mol-%) in dry 
CH2Cl2 (1.0 mL). The reaction was stirred at rt overnight. According to TLC-analysis, 
mostly baseline material had been formed, probably due to the cleavage of the BOC-
protection under the acidic reaction media.  
 
5.25. 4,6-Dideoxy-4-(N-tert-butoxycarbonyl-N-methyl)amino-α-D-
galactopyranosyl fluoride 318a 
 
O
NMeBOC
AcO
O
NMeBOC
HO
F F
274a 318a
HOAcO
 
 
To a cooled (0 °C) solution of compound 274a (109 mg, 0.30 mmol, 100 mol-%) in 
MeOH (3 mL) was added NaOMe (0.50 mL, 0.1 M) and the reaction was stirred at 0 °C 
for 2 hours. The reaction mixture was neutralized by filtration through a pad of silica and 
washed with cold MeOH. Evaporation and purification by flash chromatography (silica, 
gradient of 20 % EtOAc/hex to 50 % EtOAc/hex) afforded compound 318a (60 mg, 71 %) 
as a white solid. Crystallization from EtOAc/hex afforded white needles. Rf (50 % 
EtOAc/hex) = 0.15. Mp. 132-133 oC. [α]D20 = +68.2 (c = 1.00, MeOH). 1H NMR (400 
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MHz, CD3OD) δ 5.58 (d, 1H, J = 53 Hz), 4.51, 4.50 (dd, 1H, J = 6.3 Hz, 3.4 Hz), 4.40-
4.31 (m, 1H), 4.13-3.99 (m, 1H), 3.87, 3.84 (td, 1H, J = 26 Hz, 10.6 Hz, 2.6 Hz), 2.99, 
2.97 (s, 3H), 1.47, 1.46 (s, 9H), 1.20, 1.18 (d, 3H, J = 6.3 Hz). 13C NMR (100 MHz, 
CD3OD) δ 159.4, 159.2, 109.0 (JCF = 224 Hz), 81.4, 81.1, 70.1 (JCF = 25 Hz), 70.0 (JCF = 
25 Hz), 69.6 (JCF = 4 Hz), 69.0 (JCF = 5 Hz), 59.4, 58.2, 34.0, 33.5, 28.7, 16.8, 16.6. 
HRMS: m/z calcd for C12H22FNO5 (M+Na)+ 302.1380, found 302.1372. 
 
5.26. 4,6-Dideoxy-4-(N-tert-butoxycarbonyl-N-methyl)amino-β-D-
galactopyranosyl fluoride 318b 
 
O
NMeBOC
AcO
O
NMeBOC
HOF F
318b274b
HOAcO
 
 
Method 1: To a cooled (0 °C) solution of compound 274b (148 mg, 0.407 mmol, 100 mol-
%) in MeOH (5 mL) was added NaOMe (0.66 mL, 0.1 M) and the reaction was stirred at 0 
°C for 4 hours. The reaction mixture was neutralized by filtration through a pad of silica 
and washed with cold MeOH. Evaporation and purification by flash chromatography 
(silica, gradient of 20 % EtOAc/hex to 50 % EtOAc/hex) yielded compound 318b (84 mg, 
74 %) as a white solid. Crystallization from EtOAc/hex afforded white needles. 
Method 2: To a cooled (0 °C) solution of compound 274b (172 mg, 0.473 mmol, 100 mol-
%) in MeOH (5 mL) was added K2CO3 (6.5 mg, 47 µmol, 10 mol-%) and the reaction was 
stirred at 0 °C for 4 hours. The reaction mixture was neutralized by filtration through a pad 
of silica and washed with cold MeOH. Evaporation and purification by flash 
chromatography (silica, gradient of 20 % EtOAc/hex to 50 % EtOAc/hex) afforded 
compound 318b (93 mg, 70 %) as a white solid, which was crystallized from EtOAc/hex. 
Rf (50 % EtOAc/hex) = 0.16. Mp. 172-173 oC. [α]D20 = +17.4 (c = 1.00, MeOH). 1H NMR 
(400 MHz, CD3OD) δ 5.00, 4.99 (dd, 1H, J = 53 Hz, 6.5 Hz), 4.45-4.36 (m, 1H), 4.01-3.93 
(m, 1H), 3.83-3.66 (m, 2H), 3.03, 3.00 (s, 3H), 1.47, 1.46 (s, 9H), 1.25, 1.23 (d, 3H, J = 
6.3 Hz). 13C NMR (100 MHz, CD3OD) δ 159.4, 159.1, 112.0 (JCF = 211 Hz), 81.4, 81.1, 
73.3 (JCF = 20 Hz), 73.2 (JCF = 21 Hz), 72.9 (JCF = 12 Hz), 72.3 (JCF = 4 Hz), 58.9, 57.8, 
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34.0, 33.5, 28.6, 16.8, 16.6. HRMS: m/z calcd for C12H22FNO5 (M+Na)+ 302.1380, found 
302.1391. 
 
5.27. 2-O-Benzoyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)amino-α-D-galactopyranosyl fluoride 275a 
 
O
NMeBOC
HO
O
NMeBOC
HO
FF
318a 275a
BzOHO
 
 
A mixture of 318a (66 mg, 0.24 mmol, 100 mol-%), Et3N (0.33 mL, 2.4 mmol, 1000 mol-
%), Bu2SnO (71 mg, 0.28 mmol, 120 mol-%) and 4Å molecular sieves in benzene (5 mL) 
was refluxed for 2 h. The reaction mixture was allowed to cool down for a while before 
addition of benzoyl chloride (30 µL, 0.26 mmol, 110 mol-%). After refluxing for 10 min, 
the reaction mixture was filtered and evaporated to dryness to afford the crude 275a, which 
was directly chromatographed (silica, 10 % EtOAc/hex) to give compound 275a (42 mg, 
46 %; corrected yield 75 % based on recovered starting material) as a white solid. Rf (30 % 
EtOAc/hex) = 0.58. Mp. 104-106 oC. [α]D20 = +81.0 (c = 1.00, CHCl3). 1H NMR (400 
MHz, CDCl3)  δ 8.09 (d, 2H, J = 7.3 Hz), 7.58 (t, 1H, J = 7.5 Hz, 7.3 Hz), 7.45 (t, 2H, J = 
7.5 Hz), 5.86 (dd, 1H, J = 54 Hz, 2.9 Hz), 5.28 (dd, 1H, J = 24 Hz, 11.0 Hz), 4.70 (bs, 1H), 
4.56-4.47 (m, 2H), 3.11 (s, 3H), 1.46 (s, 9H), 1.32 (d, 3H, J = 6.7 Hz). 13C NMR (100 
MHz, CDCl3) δ 166.3, 158.7, 133.4, 129.9, 129.2, 128.4, 104.7 (JCF = 227 Hz), 80.5, 70.9 
(JCF = 24 Hz), 67.7 (JCF = 5 Hz), 67.1, 56.9, 33.3, 28.2, 16.3. HRMS: m/z calcd for 
C19H26FNO6 (M+Na)+ 406.1642, found 406.1645. 
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5.28. 2-O-Benzoyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-methyl)-
amino-β-D-galactopyranosyl fluoride 275b and 3-O-Benzoyl-4,6-
dideoxy-4-(N-tert-butoxycarbonyl-N-methyl)amino-β-D-
galactopyranosyl fluoride 320 
 
O
NMeBOC
HO
O
NMeBOC
HO
O
NMeBOC
BzO FF F
HO BzO HO
318b 275b 320  
 
A mixture of 318b (82 mg, 0.29 mmol, 100 mol-%), Et3N (0.41 mL, 2.9 mmol, 1000 mol-
%), Bu2SnO (88 mg, 0.35 mmol, 120 mol-%) and 4 Å molecular sieves in benzene (4 mL) 
was refluxed for 2 h. The reaction mixture was allowed to cool down for a while before 
addition of benzoyl chloride (37 µL, 0.32 mmol, 110 mol-%). After refluxing for another 
20 min, the reaction mixture was filtered and evaporated to dryness to afford a mixture of 
monobenzoylated fluorides. The crude product mixture was directly chromatographed 
(silica, 10 % EtOAc/hex) to give compounds 275b (79 mg, 70 %) and 320 (28 mg, 25 %) 
as white solids. Both the products were crystallized from EtOAc/hex to afford white 
needles. 
275b: Rf (30 % EtOAc/hex) = 0.28. Mp. 126-127 oC. [α]D20 = +6.5 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3)  δ 8.07 (d, 2H, J = 7.3 Hz, 1.4 Hz), 7.58 (tt, 1H, J = 7.5 Hz, 7.3 
Hz, 1.2 Hz), 7.45 (tt, 2H, J = 7.5 Hz, 1.6 Hz), 5.48-5.41 (m, 1H), 5.31 (dd, 1H, J = 52 Hz, 
7.3 Hz), 4.61 (bs, 1H), 4.17 (m, 1H), 4.01 (bs, 1H), 3.17 (s, 3H), 1.45 (s, 9H), 1.38 (d, 3H, 
J = 6.5 Hz). 13C NMR (100 MHz, CDCl3) δ 166.0, 158.5, 133.4, 129.9, 129.3, 128.4, 107.8 
(JCF = 214 Hz), 80.6, 73.0 (JCF = 23 Hz), 71.1 (JCF = 14 Hz), 56.4, 33.4, 28.3, 16.4. 
HRMS: m/z calcd for C19H26FNO6 (M+Na)+ 406.1642, found 406.1658. 
320: Rf (30 % EtOAc/hex) = 0.40. Mp. 173-174 oC. [α]D20 = +26.1 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 8.00 (d, 2H, J = 7.9 Hz), 7.55 (q, 1H, J = 7.2 Hz), 7.45-7.39 
(m, 2H), 5.32-5.24 (m, 1H), 5.19 (dd, 1H, J = 52 Hz, 7.3 Hz), 4.82-4.63 (m, 1H), 4.31-4.12 
(m, 1H), 4.05-4.00 (m, 1H), 3.13, 3.10 (s, 3H), 1.33 (d, 3H, J = 6.3 Hz), 1.24, 1.13 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 166.0, 165.7, 156.8, 156.3, 133.5, 133.3, 129.9, 129.8, 
129.4, 129.2, 128.6, 128.3, 110.2 (JCF = 212 Hz), 110.1 (JCF = 211 Hz), 80.5, 80.1, 73.6 
(JCF = 12 Hz), 73.2 (JCF = 12 Hz), 71.4 (JCF = 3 Hz), 71.2 (JCF = 4 Hz), 70.4 (JCF = 23 Hz), 
133 
69.9 (JCF = 24 Hz), 54.9, 53.7, 33.3, 32.8, 28.0, 27.9, 16.3, 16.2. HRMS: m/z calcd for 
C19H26FNO6 (M+Na)+ 406.1642, found 406.1637. 
 
5.29. 2,3-O-Dibenzoyl-4,6-dideoxy-4-(N-tert-butoxycarbonyl-N-
methyl)-amino-β-D-galactopyranosyl fluoride 321 
 
O
NMeBOC
HO
O
NMeBOC
HO
O
NMeBOC
BzO FF F
O
NMeBOC
BzO F
HO BzO HO BzO
318b 275b 320 321  
 
To a cooled (0 °C) solution of 318b (62 mg, 0.22 mmol, 100 mol-%) and DMAP (3 mg, 
0.02 mmol, 10 mol-%) in pyridine (1 mL) was added BzCl (39 µL, 0.33 mmol, 150 mol-
%) and the reaction was allowed to warm up to rt. After stirring at rt overnight the reaction 
was poured to distilled H2O and extracted with CH2Cl2. The combined organic layers were 
washed with 1 M HCl and saturated NaHCO3. Drying over MgSO4 and concentration 
afforded a crude mixture of mono- and dibenzoylated products 275b, 320 and 321. An 
analytical sample of the dibenzoate 321 was purified by flash chromatography. Rf (30 % 
EtOAc/hex) = 0.52. 1H NMR (400 MHz, CDCl3) δ 8.00-7.93 (m, 4H), 7.55-7.47 (m, 2H), 
7.42-7.34 (m, 4H), 5.95-5.82 (m, 1H), 5.59-5.46 (m, 1H), 5.44 (td, 1H, J = 52 Hz, 6.8 Hz), 
4.97-4.78 (m, 1H), 4.18-4.12 (m, 1H), 3.28, 3.24 (s, 3H), 1.41, 1.40 (d, 3H, J = 6.1 Hz), 
1.16 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 165.3, 165.2, 156.8, 156.1, 133.5, 133.6, 
133.2, 129.8, 129.4, 129.2, 129.0, 128.7, 128.6, 128.4, 128.3, 107.9 (JCF = 216 Hz), 80.5, 
80.1, 71.7, 71.6, 71.2 (JCF = 14 Hz), 71.1 (JCF = 12 Hz), 69.9 (JCF = 24 Hz), 69.7 (JCF = 23 
Hz), 55.0, 53.8, 33.3, 32.8, 28.0, 27.9, 16.3. HRMS: m/z calcd for C26H30FNO7 (M+Na)+ 
510.1904, found 510.1893. 
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5.30. 1,2,3,4-Tetra-O-acetyl-D-xylopyranose 323 
 
O
HO
OH
O
AcO
OAc
HO AcO
HO AcO
322 323  
 
D(+)-Xylose 322 (1.00 g, 6.67 mmol, 100 mol-%), Ac2O (3.14 mL, 33.3 mmol, 500 mol-
%), Et3N (7.43 mL, 53.3 mmol, 800 mol-%) and DMAP (163 mg, 1.33 mmol, 20 mol-%) 
were stirred in CH2Cl2 (100 mL) at rt for 3 h. Distilled water (50 mL) was added and the 
aqueous layer was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
washed with 1 M HCl (2 x 50 mL) and brine (50 mL), dried over Na2SO4 and 
concentrated. Purification by flash chromatography (silica, 50 % EtOAc/hex) afforded 2:1 
mixture of α-and β-anomers 323 (2.12 g, quant.) as a colorless oil. Rf (30 % EtOAc/hex) = 
0.29. 1H NMR (400 MHz, CDCl3) δ 6.23 (d, 1H, J = 3.6 Hz), 5.70 (d, 1H, J = 6.8 Hz), 
5.44 (t, 1H, J = 9.9 Hz, 9.7 Hz), 5.18 (t, 1H, J = 8.4 Hz, 8.2 Hz), 5.04-4.92 (m, 2 x 2H), 
4.12 (dd, 1H, J = 12.0 Hz, 5.0 Hz), 3.91 (dd, 1H, J = 11.1 Hz, 6.0 Hz), 3.69 (t, 1H, J = 
11.1 Hz, 10.9 Hz), 3.50 (dd, 1H, J = 12.0 Hz, 8.4 Hz), 2.15 (s, 3H), 2.08 (s, 3H), 2.03, 
2.02, 2.00 (s, 2 x 9H). 13C NMR (100 MHz, CDCl3) δ 170.0, 169.7, 169.6, 169.2, 168.9, 
92.0, 89.1, 70.9, 69.5, 69.3, 68.6, 68.3, 62.7, 60.6, 20.8, 20.7, 20.6, 20.5, 20.4. 
 
5.31. Phenyl 2,3,4-tri-O-acetyl-1-thio- β-D-xylopyranoside 250 
 
O
AcO
OAc
O
AcO SPh
AcO AcO
AcO AcO
323 250  
 
To a solution of tetra-O-acetyl-D-xylopyranose 323 (504 mg, 1.58 mmol, 100 mol-%) in 
dry CH2Cl2 (2 mL) were added thiophenol (0.19 mL, 1.90 mmol, 120 mol-%) and 
BF3.OEt2 (0.60 mL, 4.75 mmol, 300 mol-%) at 0 oC under argon. The solution was stirred 
at rt for 2 h and then diluted with CH2Cl2 (2 mL). The resulting solution was washed 
successively with saturated NaHCO3 (2 x 6 mL) and water (2 x 4 mL), dried over Na2SO4 
and concentrated. Purification by flash chromatography (silica, 10 % EtOAc/hex) afforded 
the β-anomer 250 (370 mg, 63 %) as a white solid. Rf (30 % EtOAc/hex) = 0.40. Mp. 77-
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79 °C, lit.3 mp. 77.6-77.9 °C. [α]D20 = -50.2 (c = 1.00, CHCl3), lit.3 [α]D20 = -54.9 (c = 
1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2H), 7.32-7.28 (m, 3H), 5.19 
(t, 1H, J = 8.2 Hz), 4.96-4.89 (m, 2H), 4.82 (d, 1H, J = 8.4 Hz), 4.26 (dd, 1H, J = 11.8 Hz, 
5.0 Hz), 3.43 (dd, 1H, J = 11.8 Hz, 8.9 Hz), 2.08 (s, 3H), 2.03 (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 169.5, 169.4, 169.0, 132.4, 132.0, 128.8, 127.9, 85.9, 71.8, 69.6, 68.2, 
64.9, 20.5, 20.4. 
 
5.32. 2,3,4-Tri-O-acetyl-D-xylopyranosyl-(1→3)-2-O-benzoyl-4,6-
dideoxy-4-(N-tert-butoxycarbonyl-N-methyl)amino-α-D-
galactopyranosyl fluoride 325 
 
O
AcO
O
NMeBOC
F
O
AcO SPh HO
O
NMeBOC
F
AcO
AcO BzO
AcO
AcO
BzO
325275a250
O
 
 
The donor 250 (24 mg, 65 µmol, 109 mol-%) and the acceptor 275a (23 mg, 60 µmol, 100 
mol-%) were combined and azeotropically dried with benzene (3 times). CH2Cl2 (2 mL) 
and pulverized 4Å molecular sieves were added and the mixture was stirred under argon at 
rt for 30 min. After addition of NBS (20 mg, 113 µmol, 188 mol-%) the reaction mixture 
was stirred at rt for 1.5 h. TLC analysis showed that there was still plenty of unreacted 
acceptor 275a left, and a large excess of both donor 250 and NBS was added to the 
reaction mixture. After addition the stirring was continued for 1 hour, according to TLC 
the reaction did not seem to proceed. The reaction was stopped by dilution with CH2Cl2, 
the molecular sieves were filtered off and the filtrate was washed successively with 
saturated NaHCO3 and brine. Drying over MgSO4 and concentration afforded the crude 
product mixture, which was purified by flash chromatography (silica, 15 % EtOAc/hex) to 
give a mixture of disaccharide 325 and NBS. The product was separated from NBS by 
preparative layer chromatography affording tentatively the α-analogue 325 (6.5 mg, 17 %; 
corrected yield 39 % based on recovered starting material). Rf (30 % EtOAc/hex) = 0.38. 
1H NMR (400 MHz, CDCl3)  δ 8.13-8.05 (m, 2H), 7.61-7.57 (m, 1H), 7.48-7.44 (m, 2H), 
5.80 (5.85) (dd, 1H, J = 53 Hz, 3.0 Hz), 5.78 (d, 1H, J = 4.8 Hz), 5.53 (ddd, 1H, J = 24 Hz, 
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11.2 Hz, 3.0 Hz), 5.12-5.10 (m, 1H), 4.84 (dd, 1H, J = 6.2 Hz, 3.3 Hz), 4.81-4.75 (m, 1H), 
4.53 (dd, 1H, J = 11.2 Hz, 6.2 Hz), 4.49-4.42 (m, 1H), 4.19 (ddd, 1H, J = 4.7 Hz, 2.9 Hz, 
1.0 Hz), 4.15-4.09 (m, 1H), 3.92 (dd, 1H, J = 11.9 Hz, 6.6 Hz), 3.46 (dd, 1H, J = 11.9 Hz, 
8.4 Hz) 3.12 (3.14) (s, 3H), 2.04 (s, 6H), 1.99 (s, 3H), 1.46 (1.49) (s, 9H), 1.25 (d, 3H, J = 
6.6 Hz). 13C NMR (100 MHz, CDCl3) (main rotamer) δ 169.8, 168.8, 165.7, 157.2, 133.6, 
129.8, 129.2, 128.6, 105.0 (JCF = 226 Hz), 96.9, 79.8, 73.4, 68.9, 68.5 67.9, 67.7, 67.2, 
59.0, 56.7, 33.6, 28.3, 22.3, 20.7, 15.9. HRMS: m/z calcd for C30H40FNO13 (M+Na)+ 
664.2381, found 664.2369. 
 
5.33. Attempts for disaccharide 324b 
 
5.33.1. NIS/TfOH-method 
 
The donor 250 (23 mg, 63 µmol, 120 mol-%) and the acceptor 275b (20 mg, 52 µmol, 100 
mol-%) were combined and stirred in CH2Cl2 (2 mL) with 4Å molecular sieves under 
argon at rt for 1 h. The reaction mixture was cooled to -40°C and NIS (18 mg, 78 µmol, 
150 mol-%) and TfOH (52 µmol, 100 mol-%, 1.0 M solution in CH2Cl2) were added. After 
stirring the reaction mixture at cold for 1 h, normal aqueous work-up was performed for 
the crude product mixture. No disaccharide 324b was obtained. 
 
5.33.2. NBS/TMSOTf-method 
 
The donor 250 (34 mg, 92 µmol, 180 mol-%) and the acceptor 275b (20 mg, 52 µmol, 100 
mol-%) were combined and stirred in CH2Cl2 (2 mL) with 4Å molecular sieves under 
argon at rt for 1 h. NBS (23 mg, 130 µmol, 23 mol-%) and TMSOTf (104 µmol, 20 mol-
%, 0.1 M solution in CH2Cl2) were added to the reaction, and the mixture was stirred at rt 
for 3 h. The reaction was stopped although not all the starting material had been consumed, 
and aqueous work-up for the crude mixture was performed. Unidentified products below 
the starting materials were isolated. 
 
 
137 
5.34. Attempted N-methylation for 273 by 2,6-di-tert-butyl-4-
methylpyridine and MeOTf 
 
O
NHBOC
AcO
O
NMeBOC
AcO
F FAcO AcO
273 274
x
 
 
To a cooled solution (-15 °C, ice-NaCl-bath) of compound 273 (55 mg, 0.16 mmol, 100 
mol-%) in CH2Cl2 (2.2 mL) was added 2,6-di-tert-butyl-4-methylpyridine (34 mg, 0.17 
mmol, 105 mol-%) dissolved in CH2Cl2 (1 mL). After stirring for 5 min, MeOTf (18 µL, 
0.17 mmol, 105 mol-%) was added and the reaction was stirred at rt overnight. The 
reaction was quenched with 0.5 M H3PO4 and the aqueous layer was extracted with 
EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and 
evaporated. Starting material was recovered unchanged. 
 
5.35. Attempted N-methylation for 271 by 2,6-di-tert-butyl-4-
methylpyridine and MeOTf 
 
O
OAc
OAc
NHBOC
Me
O
O
OAc
OAc
NMeBOC
Me
O
x
271 313  
 
See experimental procedure as for compound 273 in 5.34. Starting material was recovered 
unchanged. 
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